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ABSTRACT 
Louise Caroline Giffin: Manipulation and Exploitation of the Host Cell by             
Kaposi’s Sarcoma-Associated Herpesvirus 
(Under the direction of Blossom Damania) 
 
 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a human gamma-
herpesvirus that is the causative agent of three human malignancies: Kaposi’s sarcoma, 
primary effusion lymphoma, and multicentric Castleman’s disease. KSHV causes a 
lifelong infection for which there is no known cure, and the cancers associated with 
KSHV typically have poor prognosis and no established treatment protocol. KSHV is a 
large DNA virus that encodes over eighty open reading frames that have diverse 
functions, including viral proteins that thwart the host immune system and that alter 
cellular growth pathways to promote viral persistence, with the incidental effect of 
inducing cellular transformation.  
 KSHV expresses several homologs of human proteins, including a homolog of 
interleukin 6 (hIL-6) called viral interleukin 6 (vIL-6). vIL-6 is a predominantly 
intracellular protein that localizes to the endoplasmic reticulum where it can signal 
through the gp130 subunit of the IL-6 receptor. We sought to examine how vIL-6 
interacts with components of the host cell and alters host gene expression to promote 
vIL-6 function and induce pathogenesis. We identified hypoxia upregulated protein 1 
(HYOU1) as a vIL-6-interacting partner, and found that HYOU1 supports vIL-6 protein 
expression and promotes vIL-6-mediated signaling, migration, and survival in 
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endothelial cells. We also found that vIL-6 significantly upregulates the expression of 
genes associated with cellular movement including the adhesion factor called 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). We 
determined that vIL-6 increases CEACAM1 expression via STAT3 signaling, and that 
CEACAM1 promotes vIL-6-mediated migration of endothelial cells. Both de novo and 
latent KSHV infection were also found to upregulate CEACAM1.  
 To further elucidate how KSHV modulates the cellular environment, we 
performed kinome profiling to identify cellular kinases that are differentially activated 
during latent and lytic KSHV infection in primary effusion lymphoma. Kinases regulate 
almost all cellular processes, and dysregulated kinase activation can drive 
tumorigenesis. This research may identify major pathogenic signaling pathways that are 
hyperactivated or shut off in KSHV-associated cancers. Further elucidating how KSHV 
and its encoded proteins alter the cellular environment to promote pathogenesis will 
identify targets for the development of novel therapeutics to treat KSHV-associated 
disease.  
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CHAPTER 1: KSHV: PATHWAYS TO TUMORIGENESIS AND            
PERSISTENT INFECTION1,2 
 
OVERVIEW 
Kaposi’s sarcoma associated herpesvirus (KSHV; also known as human 
herpesvirus 8) is the etiological agent of Kaposi’s sarcoma, primary effusion 
lymphoma, and multicentric Castleman’s disease. These cancers often occur in the 
context of immunosuppression, which has made KSHV-associated malignancies an 
increasing global health concern with the persistence of the AIDS epidemic. KSHV 
has also been linked to several acute inflammatory diseases. KSHV exists between 
a lytic and latent lifecycle which allow the virus to transition between active 
replication and quiescent infection. KSHV encodes a number of proteins and small 
RNAs that are thought to inadvertently transform host cells while performing their 
functions of helping the virus persist in the infected host. KSHV also has an arsenal 
of components that aid the virus in evading the host immune response, which help 
the virus establish a successful lifelong infection. In this comprehensive review, we 
will discuss the diseases associated with KSHV infection, the biology of latent and 
                                                          
1 Louise Giffin and Blossom Damania. Manuscript was written by LG and edited by 
BD.  
2 Reprinted from Advances in Virus Research, Volume 88, Louise Giffin and 
Blossom Damania, “KSHV: Pathways to Tumorigenesis and Persistent Infection”, 
Pages 111-159, 2014, with permission from Elsevier. 
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lytic infection, and individual proteins and microRNAs that are known to contribute to 
host cell transformation and immune evasion.  
 
 
INTRODUCTION 
 Kaposi’s sarcoma-associated herpesvirus (KSHV) was identified in 1994, and 
is the eighth and most recently discovered human herpesvirus. Shortly after, KSHV 
was found to be the etiological agent of three human malignancies including its 
namesake, Kaposi’s sarcoma, as well as two B cell lymphoproliferative diseases 
called primary effusion lymphoma and multicentric Castleman’s disease. Recently, 
KSHV has also been associated with several acute inflammatory diseases. KSHV 
infection typically occurs in the context of immunosuppression; thus KSHV-
associated cancers have become a global public health concern alongside the acute 
inflammatory disease syndrome (AIDS) epidemic.  
 Like all herpesviruses, KSHV infection transitions between a quiescent latent 
and replicative lytic life cycles. KSHV encodes an arsenal of viral proteins and non-
coding RNAs that are thought to manipulate the host cell environment to directly or 
indirectly drive pathogenesis and viral persistence. Unlike other human pathogens 
such as bacteria, fungi, and parasites, viruses must enter the host cell to replicate 
and rely on the function of many host factors to successfully propagate. Because of 
this intimate relationship between host and pathogen, viruses have evolved in close 
contact with cellular components and thus have developed unique ways of 
manipulating and exploiting the cellular environment to support viral infection. During 
co-evolution with the human host, herpesviruses also acquired the genetic material 
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to encode homologs of cellular proteins. Some of these homologs allow the virus to 
activate or inactivate key host pathways to the virus’ advantage. Dissecting the 
function and role of individual viral components has helped create a picture of how 
KSHV induces disease. Understanding the mechanisms by which KSHV maintains a 
persistent infection and/or drives tumor development will help uncover potential 
therapeutic targets for the treatment of KSHV-associated malignancies. 
 
MALIGNANCIES AND SYNDROMES LINKED WITH KSHV INFECTION  
Kaposi’s sarcoma: The classical form of Kaposi’s sarcoma was first 
described in 1872 as a pigmented sarcoma of the skin by the Hungarian 
dermatologist, Moritz Kaposi (1). KS incidence rates started to increase dramatically 
with the onset of the AIDS epidemic in the 1980’s (2). The correlation between HIV-
infected individuals and KS suggested an infectious agent was involved. About a 
decade later, representational difference analysis used by Chang and Moore 
identified novel gammaherpesvirus DNA sequences in KS lesion biopsies (3). In the 
years following the discovery of KSHV, PEL and MCD were also found to be 
causally linked to this human herpesvirus (4-6) (Table 1). 
There are four forms of KS that have been described (7-9). Classic KS, which 
was first identified by Moritz Kaposi, is found in elderly men of Mediterranean and 
eastern European descent (10). This form of KS is characterized by benign lesions 
on the upper and lower extremities, and rarely progresses to more aggressive 
disease. The second type of KS is African endemic KS, which occurs in eastern and 
central African countries (7, 11). The lymphadenopathic form of endemic KS is found 
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almost exclusively in young African children and cause significant mortality (12, 13). 
AIDS-associated, or epidemic KS has become the most common type of KS in the 
past three decades, and is the most aggressive form of the disease (2, 14, 15). 
AIDS-associated KS is considered an AIDS-defining illness (16). KS is currently the 
most common malignancy associated with HIV infection, and therefore is the most 
frequent cancer in many Sub-Saharan countries (17-21). The fourth type of KS is 
iatrogenic/post-transplant KS, which is associated with the use of immune 
suppressive therapy for the prevention of organ transplant rejection (22-24). 
Interestingly, it was found that this type of KS occurs more often in KSHV-infected 
recipients rather than KSHV-negative recipients that receive an organ from a KSHV-
positive donor (25, 26).  
KS lesions typically occur cutaneously on upper and lower extremities or on 
mucosal surfaces; however, lesions may also involve lymph nodes or may occur on 
visceral organs such as lung and spleen (22, 27). The immune status of the host and 
lymph node involvement are important factors in patient prognosis. KS disease 
progresses through six stages called the patch, plaque, nodular, lymphadenopathic, 
infiltrative, and florid stage (13, 28). KS lesions are highly angiogenic and as a result 
are usually red, purple, or brown in color. Additionally, the lesion vasculature is 
leaky, which allows for extravasation of erythrocytes and infiltration of inflammatory 
cells (29). KS tumor cells are of endothelial cell origin, and the primary KSHV-
infected cells found in the lesion are highly proliferative spindle-shaped cells (30-32). 
Over 95% of KS lesions contain KSHV DNA (33), and most of the infected cells 
harbor the virus latently. Interestingly, KSHV infection of blood endothelial cells 
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(BEC) can induce expression of lymphatic endothelial cell (LEC) markers and vice 
versa. This transcriptional reprogramming results in poorly differentiated endothelial 
cells that express mixed lineage markers such as CXCR4, CD34, VEGFR3, LYVE1, 
and PROX1 (34-36). As opposed to a metastatic dissemination, KS lesions typically 
arise independently of one another; however this oligoclonality is not universal, and 
situations of monoclonal KS have also been reported (37, 38).   
 
Disease Presentation Lineage and 
primary tumor 
cell 
Clonality KSHV 
genomes 
Kaposi’s 
sarcoma 
(KS) 
Highly 
angiogenic. 
Lesions can be 
found on skin, 
visceral organs, 
or mucosal 
surfaces 
Endothelial cell 
origin; tumor cells 
are spindle cells 
with mixed blood 
and lymphatic 
endothelial cell 
markers 
Oligoclonal 
lesions 
>99% of 
tumor cells 
contain 
KSHV 
genomes 
Primary 
effusion 
lymphoma 
(PEL) 
Non-Hodgkin 
lymphoma; B-
cell expansion in 
body cavity 
B cell; CD20-; 
markers resemble 
partially 
differentiated 
plasma cells 
Monoclonal Each tumor 
cell has 50-
100 copies of 
the KSHV 
genome 
Multicentric 
Castleman’s 
disease 
(MCD) 
Plasmablastic 
variant of MCD 
B cell; IgM λ-
restricted 
plasmablasts 
Typically 
polyclonal 
Unknown 
 
Table 1.1: Characteristics of KSHV-associated malignancies 
 
Primary Effusion Lymphoma: Shortly after its association with KS, KSHV 
was identified as the etiological agent of PEL (6). PEL is a non-Hodgkin lymphoma 
(NHL) comprised of malignant, latently-infected B cells that expand within the 
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pericardial, pleural, and peritoneal body cavities (39). Unlike KS, PEL is a 
monoclonal population of B cells as evidenced by clonal immunoglobin gene 
rearrangements, and each tumor cell has a high KSHV copy number ranging from 
50-100 genomes per cell (40). Morphologically, PEL share features of both 
immunoblastic and anaplastic large-cell lymphomas (41). Most PEL express CD45 
and activation markers including CD30, CD38, and CD7, and epithelial membrane 
antigen (EMA) (42). Interestingly, PEL expresses plasma cell markers such as 
CD138, VS38c, and MUM-1/IRF4, but has relatively low expression of B-cell 
associated antigens, suggesting that PEL resembles partially differentiated plasma 
cells rather than mature B cells (42-44). Unlike other NHLs, PEL typically does not 
exhibit c-myc rearrangements or mutations in the ras, bcl2, or p53 genes (39, 42). 
PEL is frequently coinfected with the Epstein Barr virus (EBV) (42). 
 Although PEL is characterized by a malignant serous effusion lacking a solid 
tumor mass, cases of solid PEL have also been reported (45). These tumors 
typically present as an extracavitary lymphoma in extranodal or lymph node tissue 
and are composed of immunoblastic-like cells. These solid PEL are also KSHV 
positive, and have similar morphology, immunophenotype, immunoglobulin gene 
rearrangements to classical PEL (41). 
 PEL is a very aggressive lymphoma, and the average survival time is about 6 
months from diagnosis (46). The main prognostic factors that have been identified 
are the presence of highly active antiretroviral therapy (HAART) in HIV-positive 
patients before PEL diagnosis and the performance status of the patient prior to PEL 
diagnosis (46); however, it has also been suggested that the KSHV viral load may 
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also be an accurate predictor of clinical outcome of PEL patients (47). The level of 
immune suppression and the amount of circulating CD4+ lymphocytes may also 
contribute to the aggressiveness of PEL. 
 
Multicentric Castleman’s disease: Around the same time as PEL, the 
plasmablastic variant of MCD was also found to be associated with KSHV infection 
(4, 5). MCD also exists in a hyaline variant that is not associated with KSHV (48).  
MCD is an uncommon disseminated lymphadenopathy characterized by an 
abnormal proliferation of IgM λ-restricted plasmablasts within the mantle zone of B 
cell follicles (4, 49). MCD is considered non-neoplastic since the plasmablasts are 
typically polyclonal, however monoclonal B cell expansions have been observed 
(50). The plasmablasts are large with a vesicular nucleus containing one or more 
nucleoli (51). Systemic symptoms and inflammation as well as involvement of 
multiple organs often accompany MCD diagnosis (48, 52).    
KSHV coinfection is observed in almost all HIV-positive MCD, although only a 
small proportion of cells in affected lymph nodes typically harbor the virus. 
Interestingly, KSHV infection in MCD is quite lytic as compared to KS and PEL (53, 
54). KSHV is detected in less than 40% of HIV-negative MCD cases (4, 48, 52, 55); 
however, in patients coinfected with HIV and KSHV, MCD tends to be very 
aggressive with rapid disease progression. One cause of the high fatality among 
these cases is that other KSHV-associated malignancies including KS and PEL are 
frequently observed with HIV-associated MCD (56, 57). MCD progression is thought 
to be driven by dysregulated cytokine levels, including IL-6, IL-10, and vascular 
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endothelial growth factor (VEGF) (52, 58-60). In KSHV+ MCD, expression of the 
virally-encoded IL-6 (vIL-6) cytokine likely exacerbates inflammation and disease 
progression. vIL-6 can enhance cytokine signaling and further increase human IL-6 
and VEGF expression (61-64). A cohort of plasmablastic MCD patients with 
detectable vIL-6 expression were found to have a rapidly fatal clinical course as 
compared to vIL-6-negative MCD patients, suggesting the importance of cytokine 
signaling in MCD progression (55). 
KSHV-associated Inflammatory Cytokine Syndrome: In the past few 
years, several studies have reported patients that present with MCD-like 
inflammatory symptoms but lack lymphadenopathy or other pathological evidence of 
true MCD (65). These patients typically have elevated cellular and viral cytokine 
levels, including human IL-6, IL10, C-reactive protein, and the viral cytokine vIL-6 
(65). As compared to KS patients, high KSHV viral loads are also observed, 
indicative of a lytic or reactivated KSHV infection (27, 65). Concurrent KS is 
frequently observed in these patients as well. Because of the systemic inflammatory 
symptoms, the proposed name for this disease is KSHV inflammatory cytokine 
syndrome or KICS. It differs from the chronic immune activation disease sometimes 
seen in HIV patients because two requirements for a KICS diagnosis include 
detection of high KSHV viral load and vIL-6 cytokine levels (54).  
 There has been some controversy as to whether KICS is truly a distinct 
syndrome, since its diagnosis is typically made by exclusion of an MCD diagnosis.  It 
has been proposed that KICS is a heterogeneous condition or a “prodrome” that 
eventually evolves into KSHV+ MCD, although some patients never progress to this 
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point (54). Recently, a group investigated whether polymorphisms in the KSHV-
encoded microRNAs (miRNA) could be correlated with the development of KICS 
(66). They found that a higher percentage KSHV+ MCD and KICS patients had 
single nucleotide polymorphisms (SNPs) in the KSHV miRNA loci than KS patients 
or KSHV+/KS-negative control patients.  They also utilized classification tree 
analysis to determine combinations of SNPs that may predict development of 
KSHV+ MCD and KICS. Another recent case study identified a KICS patient with 
high viral loads of both KSHV and the ubiquitous human herpesvirus 6A, suggesting 
a possible role for other pathogens in development of KICS (27).  
 
KSHV Immune Reconstitution Inflammatory Syndrome: A small 
percentage of patients that begin HAART to treat advanced HIV infection exhibit a 
rapid deterioration of their clinical status. This phenomenon is known as immune 
reconstitution inflammatory syndrome (IRIS).  It is proposed that following immune 
reconstitution, the increase in functional CD4+ T cell populations causes an immune 
recognition and response to autoantigens or pathogens that were previously present 
but asymptomatic. Cases of IRIS have been reported against KSHV and other 
pathogens such as Mycobacterium tuberculosis, Mycobacterium avium, 
Cryptococcus neoformans, and human cytomegalovirus (CMV) (67). In many 
instances, treatment of the offending pathogen or use of anti-inflammatory drugs can 
improve prognosis. High morbidity is observed in patients experiencing KS flares 
following initiation of HAART (IRIS-KS), although administration of systemic 
chemotherapy can control flares and cause tumor regression (68, 69).  Interestingly, 
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one study determined that IRIS-KS patients had a significantly higher CD4+ count at 
KS diagnosis following HAART initiation than patients who did not develop IRIS, and 
that the mean time to KS diagnosis following HAART was less than 2 months (70). 
They also found that patients receiving more potent HAART regimens were more 
prone to IRIS-KS development. Beginning HAART treatment prior to advanced HIV 
infection or diagnosis of AIDS-KS decreases the chance of IRIS-KS (69). 
 
VIRAL LATENCY AND ASSOCIATED PROTEINS 
Latency is the default lifecycle for KSHV following infection of a host cell. 
During latency, the latency associated nuclear antigen (LANA) circularizes and 
tethers the viral genome to the host chromosomes by simultaneously binding both 
the terminal repeats and host histones H2A and H2B (71-73).  The viral genome is 
replicated by host machinery with each cell division, and therefore persists as it is 
passed to each daughter cell (74, 75). As mentioned, only a small portion of the viral 
genome is actively transcribed during latency, and this region is known as the 
latency locus. This locus includes the viral genes LANA, vFLIP, vCyclin, kaposin, 
and the viral microRNAs (76, 77). The LANA promoter controls expression of LANA, 
vCyclin, and vFLIP while the kaposin promoter drives expression of three kaposin 
transcripts, a bicistronic transcript for vCyclin and vFLIP, and the twelve viral pre-
miRNAs (78, 79). Additionally, PEL express vIRF3 (LANA2) during latency (80). 
Transgenic mice expressing some or all of the KSHV latency locus have phenotypes 
characteristic of KSHV malignancies (76, 81). The viral latent genes and microRNAs 
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have been investigated in depth to understand the mechanism by which KSHV 
causes disease. In this section, we will discuss a few elements of the latency locus. 
LANA: LANA is encoded by ORF73 and is KSHV’s major latency protein. It is 
responsible for tethering the viral episome to the host genome via the terminal 
repeats and histone interactions (71, 73), which allows host machinery to replicate 
and distribute the latent genome to daughter cells (72, 74, 75). The phosphorylated 
DNA-damage response protein γH2AX and the cellular replication fork factors 
Timeless and Tipin are some of the many known cellular proteins that assist LANA 
in maintaining KSHV episomes (82-84).  LANA has also been shown to positively 
and negatively affect the transcription of a number of host genes (85, 86). This is 
likely mediated through LANA’s interaction with many transcription factors (84). 
LANA can also autoregulate its expression by inducing transcription from the LANA 
promoter (87). Furthermore, LANA and the LANA homologue in rhesus rhadinovirus 
(RRV) can repress transcription of the viral lytic transactivator, RTA (replication and 
transcription activator, ORF50) to help maintain latency (88-90).  
LANA has several mechanisms by which it can promote host cell survival and 
proliferation. LANA can bind and inhibit p53 to reduce activation of p53-dependent 
reporter genes and cause chromosomal instability (91, 92). LANA can also bind and 
inactivate the tumor suppressor Rb leading to increased E2F-dependent reporter 
gene activation (93). Furthermore, LANA induces cytoplasmic β-catenin 
accumulation by binding and sequestering GSK-3β in the nucleus (94), thus allowing 
upregulation of the pro-growth proteins cyclin D and c-myc by the transcription factor 
LEF. LANA can also stabilize c-myc protein levels (95, 96). LANA has been shown 
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to increase telomerase expression, which increases the lifespan of infected cells 
(97). Finally, B cell-specific expression of LANA in a transgenic mouse model led to 
follicular hyperplasia, increased germinal center formation, and lymphomas, 
implicating LANA as a key player in KSHV-associated lymphomagenesis (81). 
vCyclin: vCyclin is another latently-expressed protein and is encoded by 
ORF72. vCyclin shares sequence and functional homology with cellular cyclin D2 
and can bind and activate the cyclin-dependent kinase CDK6 (98, 99). When in 
complex with cdk6, vCyclin can phosphorylate and inactivate the tumor suppressor 
Rb, the cdk inhibitor p27 (Kip), and the anti-apoptotic protein Bcl-2, collectively 
leading to cell cycle deregulation (100-102). vCyclin-cdk6 can also phosphorylate 
histone H1 and cdc25a (101). Interestingly, vCyclin transgenic mice develop 
lymphomas deficient in p53 (103).  This is likely because vCyclin can also bind cdk9 
which induces p53 phosphorylation and cell cycle arrest, so only cells which have 
lost p53 can continue to divide and expand into a lymphoma (104). 
vFLIP: KSHV K13 encodes vFLIP, which is a viral homolog of cellular FLIP 
(FLICE [protein FADD-like interleukin-1 beta-converting enzyme, now called 
caspase-8] inhibitory protein). vFLIP is expressed during latency, and contains two 
death effector domains that can associate with FADD and prevent the CD95 death 
receptor from activating the apoptosis-inducing protease caspase 8 (FLICE) (105). It 
was subsequently shown that vFLIP can bind procaspase 8 directly to prevent its 
cleavage into active caspase 8 (106). Furthermore, vFLIP persistently activates 
nuclear factor kappa B (NFκB) signaling through binding to IKKα, IKKβ, RIP, and the 
NEMO complex (107, 108). This signaling contributes to the transforming potential of 
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vFLIP (109). In vivo studies demonstrate that vFLIP transgenic mice can develop 
lymphomas and B cell-derived tumors (110-112).  
The Kaposins: ORF K12 encodes three transcripts that yield kaposin A, B, 
and C (113). Kaposin is highly abundant in PEL, and is transforming in cell culture-
based assays (114). Kaposin A was shown to interact with the ARF guanine 
nucleotide exchange factor cytohesin-1 to mediate cellular transformation and 
activation of the ERK/MAPK pathway (115). Kaposin B plays a role in preventing the 
decay of cytokine mRNAs by binding and activating the p38/MAPK target kinase 
MK2 (116, 117). MK2 can inhibit the decay of mRNAs that contain AU-rich elements, 
which include cytokine mRNAs and the mRNA for PROX1. KSHV induces 
reprogramming of blood vascular endothelial cells towards a lymphatic lineage 
through upregulation of PROX1, and the ability of kaposin B to stabilize PROX1 
mRNA is critical for this process (118). 
KSHV microRNAs: Similar to other members of the herpesvirus family, 
KSHV encodes 12 viral pre-microRNAs (pre-miRNAs) that are processed by the 
host proteins Drosha and Dicer to generate mature miRNAs. The KSHV pre-miRNAs 
are transcribed from the latent Kaposin/K12 promoter. While 10 of the pre-miRNAs 
are located in a Kaposin intron, the remaining 2 are located in the Kaposin protein-
coding region and the Kaposin 3’ UTR (119-121) . The 12 viral pre-miRNAs 
generate 24 mature miRNAs that have all been detected in KSHV-infected cells. 
Furthermore, RNA editing of the 5’ end of pre-miR-K12-10 can yield multiple mature 
miR-K12-10 species (122). Despite having a common promoter, the mature KSHV 
miRNAs each exist at high but variable levels in latent PEL cell lines, and miR-K12-
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10 and miR-K12-12 levels are further increased during lytic replication (121-123). In 
PEL cell lines, over 90% of the expressed mature miRNAs are KSHV miRNAs. 
Several studies comparing clinical samples of KS biopsies and PEL to cultured PEL 
cell lines report that the KSHV pre-miRNAs are expressed at even higher levels in 
vivo and that their sequences are highly conserved between patients (124, 125). 
Functional KSHV miRNAs are also found in the virion, along with mRNAs, cellular 
miRNAs, and other small RNA species (126).  
A number of validated host and viral mRNA targets of the KSHV miRNAs 
have been identified. These targets are involved in a variety of viral and cellular 
processes including maintenance of viral latency, immune evasion, cell cycle 
regulation, cell survival and proliferation, and apoptosis. miR-K9* has been shown to 
directly target the 3’ UTR of the ORF50/RTA mRNA to prevent lytic reactivation 
(127), and miR-K12-5 may also indirectly suppress the RTA transcript (128). 
Furthermore, miR-K12-4 can target the DNA methyltransferase repressor Rbl2 to 
epigenetically maintain latency (128), and miR-K12-1 targets the 3’ UTR of the NFκB 
repressor IκBα to enhance NFκB signaling and promote latency (129). Two 
components of the TLR/IL-1R signaling cascade, IRAK1 and MyD88, were identified 
as targets of miR-K12-9 and miR-K12-5, respectively, which results in reduced IL-6 
and IL8 inflammatory cytokine production (130). Furthermore, miR-K12-7 can 
directly bind the 3’ UTR of the mRNA of MICB, the stress-induced natural killer (NK) 
cell ligand, to repress MICB translation and promote viral immune evasion by 
diminishing NK cell function (131). KSHV miR-K12-1 is able to prevent cell cycle 
arrest by targeting the CDK inhibitor p21 to promote cell division (132). KSHV 
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infection may prime B cells for transformation by expression of miR-K12-11, which is 
an ortholog of cellular miR-155 (133-135). miR-K12-11 targets the host protein 
Jarid2 and both miR-155 and miR-K12-11 can induce expansion of splenic CD19+ B 
cells in vivo (133, 136). Additionally, miR-K12-11 and -1 can induce MAPK signaling, 
promigration factors, and cell invasiveness through indirectly suppressing the MAPK 
phosphatase DUSP1 (137).  
The KSHV miRNAs also have several mechanisms of preventing apoptosis of 
host cells: miR-K12-10 variants inhibit TGF-β signaling by targeting the 3’ UTR of the 
TGF-β type II receptor (TβRII) (138) and miR-K12-10a suppresses the tumor 
necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) receptor (TWEAKER) 
to prevent TWEAK-mediated caspase activation, apoptosis, and proinflammatory 
cytokine production (139). Furthermore, it was demonstrated that miR-K12-1, -3, and 
4-3p can target the 3’ UTR of caspase 3 to downregulate this host protein and inhibit 
apoptosis (140). The KSHV miRNAs have a variety of cellular and viral targets, only 
a handful of which have been discussed here. Collectively, the miRNAs work to drive 
KSHV pathogenesis by promoting latency, providing favorable growth conditions, 
and preventing apoptosis of infected cells.   
In addition to the genes described above, some reports have also shown that 
viral genes such as K1, vIL-6, and K15 are expressed at low levels during latency 
but are highly upregulated during lytic replication (141-143). These viral proteins are 
discussed in the section on lytic pro-growth proteins. 
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THE KSHV LYTIC CYCLE 
The KSHV lytic cycle can ensue following primary infection or when a latently 
infected cell undergoes lytic reactivation.  During the lytic cycle, a temporal 
transcriptional cascade begins that results in expression of viral immediate early, 
delayed early, and late genes followed by the subsequent assembly and egress of 
progeny virions (144). As discussed earlier, a variety of cell stresses can induce 
reactivation (145-149). Ultimately, expression of the lytic transactivator, ORF50/RTA, 
is required to initiate this complex stage of the viral lifecycle. RTA expression alone 
is sufficient to drive lytic replication, and suppression of RTA prevents reactivation 
(150-153). RTA is an immediate-early gene, and it is part of a polycistronic transcript 
that also encodes K8 and K8.1. Other immediate early genes include ORF45 and 
K4.2 (154). RTA has an activation domain and a DNA-binding domain on opposite 
ends of the protein. The DNA-binding domain allows RTA to directly bind and 
activate numerous viral promoters and the two KSHV origins of lytic replication, 
OriLyt-L and OriLyt-R (155, 156). The activation domain allows RTA to interact with 
cellular transcription factors and chromatin modification complexes to promote viral 
gene transcription (157).   
 Delayed early genes are sensitive to cyclohexamide treatment because in 
order to be transcribed they require the function of the proteins encoded by 
immediate early genes.  The delayed early genes include the viral DNA polymerase 
and viral proteins required for viral DNA synthesis, as well as the viral thymidine 
kinase, nucleotide reductase, ORF57, the signal transduction proteins K1, K15, and 
vGPCR, and the immune evasion proteins K3 (MIR1) and K5 (MIR2) (144). 
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Following expression of the delayed early genes, viral DNA replication begins from 
OriLyt-L and OriLyt-R (158, 159). The viral replication machinery includes the viral 
DNA polymerase, helicase, polymerase processivity factor, primase, primase-
associated factor, and single strand binding protein (160) and replication is thought 
to occur by a rolling circle mechanism similar to other herpesviruses. Viral DNA 
replication stimulates expression of the KSHV late genes, which mainly encode 
structural proteins such as the viral capsid and envelope proteins (161). Linear 
genomes are packaged into the newly forming capsids. KSHV ORF67 and ORF69 
assist in nuclear egress (162, 163), and KSHV glycoprotein B is thought to play a 
role in viral maturation and egress from the host cell (164, 165). 
 
LYTIC KSHV PROTEINS INVOLVED IN CELL GROWTH AND SURVIVAL  
Lytic reactivation results in expression of all KSHV genes. As described 
earlier, several of the proteins encoded by the KSHV latency locus can drive cellular 
transformation. A number of proteins encoded by KSHV lytic genes also have pro-
growth or transforming qualities, which are discussed in this section and 
summarized in Figure 1.1. 
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Figure 1.1: KSHV encodes a number of proteins that contribute to cell growth and 
transformation. A) K1 is a transmembrane protein with a constitutively active 
immunoreceptor tyrosine activation motif (ITAM) that activates signaling through SH2-
containing proteins. K1 expression results in production of VEGF and pro-inflammatory 
cytokines. B) vGPCR is a constitutively active homolog of the IL8 receptor  that results in 
activation of numerous cell signaling pathways and transcription factors to increase 
production of VEGF, VEGFR, and proinflammatory cytokines and chemokines. C) vIL-6 is a 
functional homolog of human IL-6 that can signal through shared IL-6 pathways including 
JAK/STAT, MAPK, and PI3K. This results in activation of multiple IL-6 response elements 
and production of human IL-6 and VEGF. D) K15 is a transmembrane protein with several 
tyrosine residues and SH2 and SH3 domains in its cytoplasmic tail that are critical for K15’s 
interaction with cellular TRAFs and signaling through  the MAPK and NFκB pathways. K15  
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signaling results in activation of numerous transcription factors and expression of pro-
inflammatory cytokines and chemokines and several human miRNAs that are involved in cell 
motility. 
 
K1: K1 is a single-pass transmembrane glycoprotein encoded by the first 
open reading frame of KSHV (Figure 1.1 A). This protein is expressed on the cell 
and ER membranes and can be internalized to endosomes (166, 167).  K1 is 
constitutively active and has a highly conserved intracellular immunoreceptor 
tyrosine-based activation motif (ITAM) on its C terminus (168-170). Upon K1 
oligomerization, the ITAM becomes autophosphorylated and can activate various 
Src homology 2 (SH2)-containing signaling proteins including PI3K (p85)/Akt, PLCγ, 
Vav, Syk, Lyn, RasGAP, and Grb2 (171-173). Additionally, ITAM signaling results in 
activation of NFκB, nuclear factor of activated T cells (NFAT), Oct-2 and AP-1(173, 
174).  
Endothelial cells expressing K1 become immortalized in culture and primary 
marmoset T lymphocytes infected with a K1-expressing herpesvirus saimiri became 
immortalized to IL2-independent growth (175, 176).  K1 can also induce focus 
formation in rat fibroblasts (176). In vivo, K1 transgenic mice display constitutively 
active NFκB and Src family tyrosine kinase signaling and a fraction of the mice 
develop tumors (174) There are several aspects of K1 signaling that likely contribute 
to its transforming function. K1’s activation of Akt results in inactivation of the 
proapoptotic forkhead (FKHR) transcription factor family which protects cells from 
FKHR- and Fas-mediated apoptosis (171). Heat shock protein-90 and -40 (hsp90 
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and hsp40) were identified as K1 binding partners that are critical for both K1 
expression and K1’s anti-apoptotic function (177). K1 also induces angiogenesis and 
VEGF production in primary human endothelial cells and cells derived from K1 
transgenic animals (173, 175, 178). Furthermore, K1 signaling can induce secretion 
of inflammatory cytokines that are implicated in KS lesion development, including IL-
6, GM-CSF, IL-1β, IL-8, and IL-10 (172, 174). A unique mechanism that K1 utilizes 
to prolong the life of B cells is to downregulate surface expression of the B cell 
receptor (BCR) by binding the µ chain of the BCR to retain the complex in the ER 
(179). Overall, K1 is a multifunctional protein that can constitutively activate multiple 
pro-growth signaling pathways in KSHV infected cells. 
Viral G protein Coupled Receptor (vGPCR): KSHV ORF 74 encodes the 
vGPCR, which is a seven-pass transmembrane protein that shares homology with 
the human IL8 receptor (Figure 1.1 B) (180). This lytic protein has been detected at 
low levels in cultured reactivated PEL and in KS, PEL, and MCD clinical specimens 
(181). Conflicting reports have demonstrated that vGPCR has the ability to both 
sustain (182) and repress (183) RTA expression and lytic replication. Although 
vGPCR can bind the CXC and CC families of chemokines, it is constitutively active 
even in the absence of ligand (184-186).  vGPCR activates a number of important 
signaling pathways, including PLC, PKC, MAPK, PI3K/Akt/mTOR, and NFκB (187). 
Downstream signaling from these pathways activates the AP1, NFAT, NF-κB, HIF-
1α, and CREB transcription factors which results in vGPCR-mediated production of 
VEGF, VEGF receptor (VEGFR), and proinflammatory cytokines and chemokines 
(187). Through these signaling pathways, vGPCR can immortalize and promote the 
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growth of endothelial cells in culture (188-190). It was also demonstrated that 
endothelial cell-specific expression of vGPCR can cause formation of KS-like 
angioproliferative lesions in mice (191). Similar to K1, vGPCR expression can also 
transform NIH3T3 fibroblasts, as well as rat kidney cells, which are then able to form 
tumors in nude mice (186). A line of transgenic mice expressing vGPCR in 
hematopoietic cells developed angioproliferative lesions resembling KS at multiple 
organ sites (192). However, another study with a line of transgenic mice with vGPCR 
expressed ubiquitously from an SV40 promoter found that lesions mainly occurred 
on the tail and/or legs and that only a small fraction of tumor cells actually expressed 
vGPCR (193). Collectively, this research suggests a model by which vGPCR drives 
transformation of cells by inducing paracrine secretion of proinflammatory cytokines 
and angiogenic growth factors which can then work in concert with KSHV latent 
proteins to promote tumorigenesis.  
Viral Interleukin-6 (vIL-6): KSHV ORF K2 encodes the vIL-6 cytokine 
(Figure 1.1 C). vIL-6 is induced upon lytic replication, but it is also expressed at low 
levels during latency. Although vIL-6 has been detected in KSHV-associated 
malignancies (64, 194), levels are highest in MCD lesions and patient sera (55).  
This protein shares about 25% amino acid identity and 63% similarity with human IL-
6 (hIL-6) (195-197). Additionally, vIL-6 shares many functional characteristics with 
hIL-6, and as a result the viral cytokine can activate the IL-6 receptor (IL6-R) and 
downstream signaling pathways, including the JAK/STAT, MAPK, and PI3K/Akt 
pathways (198, 199). These pathways induce a variety of transcription factors and 
response elements (RE) such as the STAT1/3 and STAT5 IL-6 RE, C/EBP, and c-
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jun promoter IL-6 RE (JRE-IL-6) (62). Activation of these pathways leads to 
expression of hIL-6 (200) and VEGF (61). However, vIL-6 differs from the human 
cytokine in several regards. vIL-6 can signal intracellularly directly through the gp130 
subunit of the IL6-R and does not require the extracellularly-located IL6-R gp80 
subunit whereas hIL-6 requires both gp80 and gp130 (201-203); however, gp80 can 
still bind to vIL-6 and enhance signaling (63, 204, 205). Additionally, hIL-6 is 
secreted much more efficiently than vIL-6, and a large portion of expressed vIL-6 is 
actually retained in the endoplasmic reticulum (ER) (206, 207).  In the ER, vIL-6 
interacts with the ER chaperone calnexin which impacts vIL-6 localization and 
intracellular retention (142). Furthermore, vIL-6 undergoes N-linked glycosylation 
which is required for its signaling activities (208). 
 vIL-6 expression transforms NIH3T3 fibroblasts and these cells form tumors 
in nude mice (61). vIL-6 expression can also induce growth in mouse hybridoma 
(198), PEL (209, 210), BAF (205), and Hep3B hepatoma (195) cell lines. In 
endothelial cells, vIL-6 expression induces proliferation, tubule formation, and 
neoangiogenesis (211, 212). Additionally, vIL-6 can help cells escape interferon 
(IFN)-induced growth arrest (209).  Furthermore, transgenic mice expressing vIL-6 
under the MHC class I promoter develop plasmablastic MCD-like disease, which is 
abrogated in the absence of endogenous IL-6 (213).   
K15: KSHV K15 is encoded by the rightmost open reading frame of the virus 
(Figure 1.1 D). K15 has two highly divergent alleles called the predominant (P) and 
minor (M) forms, and these are present in different strains of KSHV (214). K15 is 
expressed at low levels in latent PEL, but is robustly induced following lytic 
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reactivation. The transcript is spliced to yield multiple K15 proteins with 4-12 
transmembrane domains that localize to lipid rafts (215, 216). The short K15 
cytoplasmic tail contains SH3 and SH2 signaling motifs and binding sites for TRAFs 
1, 2, and 3 (215, 217).  Several critical tyrosine residues within these motifs are 
constitutively phosphorylated by cellular Src family tyrosine kinases, which mediate 
activation of downstream signaling pathways.  Pathways activated by K15 signaling 
include the Ras/MAPK, JNK/SAPK, and NFκB pathways as well as the NFAT/AP1 
transcription factors (217-219). This signaling activates transcription of a number of 
cellular cytokines and chemokines including IL-6, IL-8, CCL20, CCL2, CXCL3, IL-
1α/β, and Cox2 (217, 220). K15 can also downregulate signal transduction and 
intracellular calcium mobilization induced by the BCR, which may help the virus 
maintain latency (216). A potential mechanism by which K15 accomplishes this may 
be through K15’s interaction with the tyrosine kinase Lyn, which plays a role in the 
regulation of BCR signaling (219). Additionally, the K15 M allele induces cell motility, 
and this is dependent on K15-mediated upregulation of the human miRNAs miR-21 
and -31 (221). K15 may contribute to KSHV-induced tumorigenesis through its ability 
to activate pro-growth signaling pathways, promote latency, and induce cell motility. 
 
KSHV’S ACTIVATION AND EVASION OF THE HOST IMMUNE RESPONSE 
The human immune system is designed to recognize invading pathogens in 
order to launch an innate and adaptive response to eliminate infection. KSHV utilizes 
a number of mechanisms to dampen the immune response so that it can persist for 
the lifetime of the host. In this section, we will discuss aspects of the innate and 
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adaptive immune response that are activated by KSHV infection as well as aspects 
that are suppressed by viral immune evasion techniques.  
Immune Activation: Toll-like receptors (TLR) are innate pattern recognition 
receptors that recognize pathogen-associated molecular patterns (PAMPs) and 
induce NFκB signaling and production of type I IFN and proinflammatory cytokines 
(222). KSHV can activate TLR3 during infection of primary human monocytes, and 
this upregulates TLR3 expression and the production of IFNβ and CXCL10 (223, 
224) which are then downregulated as latency is established (225). Although KSHV 
can reduce TLR4 activity in endothelial cells, TLR4 activation is still capable of 
inhibiting KSHV infection because cells lacking this receptor are more susceptible to 
infection (226). Thus, there is an initial TLR-mediated innate immune response to 
KSHV primary infection, but in many cases this response is subsequently 
downregulated by the virus. KSHV is also sensed by IFN gamma-inducible factor 
IFI-16, which triggers inflammasome formation and subsequent production of IL-1β 
(227, 228). Additionally, KSHV infection can activate plasmacytoid dendritic cells 
(pDCs) which results in TLR9-mediated production of IFNα (229).   
KSHV-associated diseases typically occur in immune compromised patients, 
and it has been demonstrated that reconstitution of the immune system can result in 
KSHV-associated tumor regression (230). This suggests a role for the adaptive 
immune response, particularly the CD8+ T cell response, in controlling KSHV 
infection and pathogenesis (231-233).  CD4+ T cells can weakly recognize KSHV 
latent antigens such as LANA (234). Additionally, it was found that CD4+ and CD8+ 
T cells from KSHV-seropositive patients frequently recognize select groups of early 
25 
lytic and late lytic KSHV genes (235). In a cohort of seven KSHV+/HIV+ KS patients 
on HAART, KSHV-specific immune responses were detected in six of the seven 
patients (236). Interestingly, 100% of the non-progressor patients had KSHV-specific 
CD8+ cytotoxic T lymphocytes (CTLs) that simultaneously secreted IFNγ and TNFα 
in response to KSHV antigen whereas only 60% of the patients with progressive 
disease had a CD8+ CTL response (236). Although most studies of the adaptive 
immune response to KSHV have investigated the T cell response, KSHV infection 
also generates a humoral response to a variety of viral antigens (237).  
Evasion of the Adaptive Immune Response: KSHV employs a variety of 
mechanisms to evade KSHV-specific adaptive immune responses (reviewed in 
(238)). These techniques mainly involve repressing viral antigen presentation, T cell 
activation, B cell receptor (BCR)-mediated B cell activation, and B cell differentiation.  
 KSHV infection of B cells, dendritic cells (DCs), macrophages, and 
endothelial cells results in decreased expression of the major histocompatibility 
complex class I (MHC-I) (239, 240). MHC-I is critical for the presentation of viral 
antigens to the T cell receptor (TCR) of CD8+ T cells. KSHV K3 and K5 (also called 
modulator of immune recognition (MIR) 1 and 2, respectively) are capable of 
ubiquitinating the MHC-I cytoplasmic tail to trigger endocytosis and proteasomal 
degradation of the complex (241, 242). vIRF1, vFLIP, and the virally-encoded shutoff 
and exonuclease protein (KSHV SOX) can also cause downregulation of MHC-I 
(243, 244). vIRF3 and cellular suppressor of cytokine signaling 3 (SOCS3) were 
recently found to inhibit antigen presentation by the MHC-II complex by reducing the 
level of MHC-II transcripts (245, 246). Additionally, vIRF3 expression renders PEL 
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resistant to recognition by KSHV-specific CD4+ T cells. LANA, which is expressed in 
all KSHV-infected cells, has an acidic central repeat domain that prevents its 
antigenic processing to further hinder this process (247, 248). In addition to 
repressing antigen presentation, KSHV infection also causes downregulation of the 
costimulatory molecules CD80, CD86, CD1a, and CD83 on antigen presenting cells 
(APCs) (249). K5 likely plays a role in this, because it has been shown to 
downregulate CD86 and ICAM-1 (250). These costimulatory molecules are required 
for TCR-mediated activation of CTLs, so the downregulation of these proteins is a 
mechanism by which KSHV infection inhibits the adaptive T cell immune response.  
As discussed previously, B cells are one of the main target cells of KSHV 
infection. B cells are a critical part of the adaptive immune response, and following 
binding of antigen to the B cell receptor (BCR), these cells proliferate and 
differentiate into antibody-producing plasma cells or memory B cells (251). 
Antibodies eliminate infection by binding to antigen that is either in the extracellular 
space or presented on the surface of infected cells.  Antibody binding generally 
results in neutralization or phagocytosis of the pathogen or infected cell. If a B cell is 
unable to be activated through its BCR or unable to differentiate into a plasma cell, 
antibody production will not occur. One hypothesis is that KSHV targets these two 
aspects of B cell biology as a mechanism of adaptive immune evasion. The KSHV 
K5 protein can utilize its ubiquitin ligase activity to downregulate bone marrow 
stromal antigen 2 (BST-2, also called tetherin) which is an IFN-inducible protein that 
plays a role in B cell differentiation (252). As mentioned earlier, the KSHV K1 
signaling protein plays a role in downregulation of the BCR on the cell surface (179). 
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Furthermore, KSHV K15 is capable of disrupting signaling from the BCR and 
possibly accelerating BCR internalization to further reduce BCR-mediated B cell 
activation (216, 253). Collectively, this inhibition of both B cell differentiation and 
BCR signaling may help KSHV evade the B cell immune response. 
Evasion of the Innate Immune Response: A large portion of the KSHV 
genome is devoted to evading the innate immune response of the host. The innate 
immune functions targeted by viral proteins include interferon production, interferon 
regulatory factor (IRF) activation, natural killer (NK) cell activity, complement 
activation, inflammasome activation, and chemokine activity. In this section we will 
discuss the strategies utilized by KSHV to hinder the innate immune response to 
allow the virus to persist for the lifetime of the host (Figure 1.2).  
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Figure 1.2: KSHV evasion of the host interferon response. KSHV encodes viral 
interferon regulatory factors (vIRF 1-3) that antagonize the function of cellular IRFs, p300, 
and NFκB to suppress production of type I IFN. ORF45, RTA, and KbZIP have also been 
shown to interfere with IRF signaling.  K3 and K5 are able to degrade the IFN3γR1 to 
reduce antiviral IFNγ signaling through the JAK/STAT pathway. Viral infection and 
expression of vGPCR reduces TLR4 expression, and RTA can induce degradation of the 
TLR3 and TLR4 mediator TRIF. miR-K12-9 and 5 downregulate IRAK1 and MYD88 which 
are also components of TLR signaling pathways. Reduction of TLR signaling results in 
reduced expression of type I IFN. Finally, ORF64 is able to deubiquitinate RIG-I which 
suppresses RIG-I mediated production of IFNβ.  
 
 KSHV employs multiple mechanisms of inhibiting both IFN production and 
signaling since IFN is a potent antiviral defense that is detrimental to KSHV 
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persistence (Figure 1.2) (254).  The virus encodes four homologs of the cellular IRFs 
called vIRF 1-4 (255). The cellular IRFs are a large family of transcription factors that 
drive expression of type I IFN (IFNα and β) and a variety of cytokines and 
chemokines. Of the four KSHV-encoded vIRFs, only vIRFs 1, 2, and 3 have been 
shown to impact IFN signaling. vIRF1 can bind to and inhibit the transcriptional 
activities of IRF1, IRF3, and IRF7 (256, 257). Additionally, vIRF1 can bind and 
sequester the transcriptional coactivator p300 that is required for IRF1- and IRF3-
mediated transcription of type I IFN (256, 257). vIRF2 is able to bind to cellular IRF1, 
2, and 8 as well as NFκB RelA and p300 (258). vIRF2 is able to block type I IFN 
signaling and  IFNα-, IFNλ-, and IRF1-dependent transactivation of the IFN 
stimulated response element (ISRE) promoter (259). More recently, IRF3 was 
identified as a binding partner of vIRF2, and it was shown that this interaction both 
suppresses IRF3-mediated transcription of IFNβ and enhances caspase-3-
dependent degradation of IRF3 (260). vIRF3 can interact with cellular IRFs 3 and 7 
which diminishes the DNA-binding abilities of IRF7 (261). vIRF3 can also interact 
with IRF5 to inhibit IRF5-mediated IFN promoter activation and production of type I 
IFN (262, 263). Recently, it was shown that vIRFs 1 and 2, but not vIRF3, are 
capable of suppressing endogenous IFNβ message and protein expression following 
activation of TLR3 (225). Because KSHV can activate and upregulate the TLR3 
pathway (223), this suggests that the vIRFs have a crucial function in evading the 
innate type I IFN response to KSHV infection. The vIRFs also have the ability to 
promote cell growth and prevent apoptosis (reviewed in (255)). Therefore, the vIRFs 
may have a twofold function in infected cells: first, to inhibit IFN to create a safe 
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environment for KSHV, and second, to promote cell survival to allow for persistence 
of the virus in the host.  
 KSHV ORF45 also influences the IFN response. It was demonstrated that 
KSHV ORF45 can interact with the inhibitory domain of cellular IRF7 (264). This 
interaction prevents IRF7’s phosphorylation and nuclear accumulation, which are 
both necessary for IRF7-mediated transcription of type I IFN (265). ORF45 also 
competes with IRF7 for phosphorylation by IKKε and TBK1 which reduces overall 
levels of IRF7 phosphorylation (266). Infection of cells with an ORF45-null virus 
triggered a strong IRF7-dependent type I IFN response that rendered them resistant 
to subsequent vesicular stomatitis virus (VSV) infection (267).  Interestingly, ORF45 
is contained within the KSHV virion, which allows the virus to dampen the IFN 
response immediately upon infection (268). KSHV RTA can also act as an E3 
ubiquitin ligase that induces the ubiquitination and degradation of IRF7 to reduce 
transcription of type I IFN genes (269). KSHV ORFK8 encodes a transcription factor 
KbZIP that can bind to the positive regulatory domain (PRD) I/III region of the IFNβ 
promoter to block IRF3-mediated IFNβ transcription (270).  
In addition to inhibition of type I IFN, KSHV can also repress signaling by 
IFNγ. The K3 and K5 proteins are able to induce degradation of the IFN-γ receptor 1 
(IFN-γR1) which normally triggers IFNγ-mediated activation of the JAK/STAT 
pathway (271). Signaling through this pathway induces expression of a wide variety 
of antiviral genes, which is suppressed following reduction of IFN-γR1 expression by 
K3 and K5 (271). Between the vIRFs, ORF45, RTA, KbZIP, K3, and K5, KSHV 
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utilizes a variety of mechanisms to evade IFN activation, suggesting the importance 
of avoiding this antiviral response in order for KSHV to persist in the host. 
 As mentioned earlier, the TLRs are pattern recognition receptors (PRR) that 
can be activated by invading pathogens. TLR activation triggers the production of 
antimicrobial cytokines and chemokines such as IFN, CCLs, and CXCLs through a 
variety of signaling proteins including NFκB, IRFs, and TRAFs. KSHV infection is 
able to downregulate TLR4 expression partly through the actions of vGPCR and 
vIRF1, and this subsequently suppresses expression of TNF-α, IL1-β, IL-6, and IFNβ 
(226). Furthermore, it was recently discovered that the ubiquitin ligase activity of 
KSHV RTA may cause the degradation of TRIF (Toll-IL-1 receptor (TIR) domain-
containing adaptor-inducing β-IFN), which is a critical mediator of TLR3- and TLR4-
induced type I IFN production (272). As mentioned previously, the KSHV-encoded 
miRNAs miR-K12-9 and miR-K12-5 target IRAK1 and MYD88, which are both 
essential components of TLR and IL-1 receptor signaling pathways (130) . 
In addition to the TLRs, which are membrane-bound PRRs, host cells also 
express cytosolic receptors. These cytosolic PRRs include the RNA helicases RIG-I 
and MDA5, the NLR (nucleotide-binding and oligomerization, leucine-rich repeat 
containing) protein family, and the cytosolic DNA sensing pathway cGAS/STING 
(cyclic GMP AMP synthase/stimulation of IFN-dependent genes). RIG-I detects viral 
RNA and becomes ubiquitinated by TRIM25, which allows it to interact with the 
downstream signaling complex MAVS/IPS-1 (273, 274). Activation of this complex 
leads to the induction of type I IFN, which can limit KSHV infection (275) KSHV 
encodes a deubiquitinase (DUB), ORF64, which is capable of deubiquitinating RIG-I 
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to suppress RIG-I-mediated activation of the IFNβ promoter during reactivation 
(276).  
NLRs sense a variety of microbial ligands, and their activation results in the 
assembly of an inflammasome complex which activates caspase-1 to generate 
mature IL-1β and IL18 (277). Production of IL-1β and IL18 in response to infection 
can lead to hyperinflammatory caspase 1-mediated cell death, called pyroptosis. 
KSHV ORF63 has homology to parts of cellular NLRP1, but lacks the effector 
caspase activation and recruitment (CARD) domain that is critical for inflammasome 
formation and function. ORF63 is able to interact with NLRP1 to prevent formation of 
both the NLRP1 and NLRP3 inflammasome and subsequent activation of caspase 1 
(278). The function of ORF63 appears to be important for supporting viral gene 
expression and genome replication as well as suppressing IL-1β production. 
A new cytosolic DNA sensor called cGAS was recently identified. cGAS 
activates the effector STING to induce IFN production and a subsequent antiviral 
response (279, 280). It was recently found that KSHV infection activates the 
cGAS/STING pathway, and employs multiple mechanisms to dampen this activation 
(281). One of these mechanisms is expression of vIRF1, which blocks the 
cGAS/STING-induced IFN response by disrupting the interaction between STING 
and the effector molecule TBK1.  
KSHV encodes three homologs of cellular chemokines: viral CC-chemokine 
ligand 1 (vCCL1, also called vMIP1), vCCL2 (vMIP2), and vCCL3 (vMIP3) (195). 
vCCL1 is a ligand and agonist of CCR8 (282), whereas vCCL2 is a ligand that 
actually blocks signaling through multiple chemokine receptors including CCR-1, -2, 
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-5, and -8 and CXCR-1, -2, and -4 (283). vCCL3 is an agonist for CCR4 (284). 
Collectively, binding of the viral chemokines to their respective cellular chemokine 
receptors is able to elicit a Th2-polarized response that is less cytotoxic to KSHV-
infected cells than a Th1-polarized response (284, 285).  
 The complement pathway acts as a bridge between the innate and adaptive 
immune system, since activation of complement can occur in an antibody-dependent 
or independent mechanism. Furthermore, phagocytosis of complement-bound 
pathogens or infected cells (opsonization) generates pathogen-derived antigens 
required to prime the adaptive immune system. Complement activation can occur 
through the classical, lectin, or alternative pathways which all result in the cleavage 
of complement component C3 into C3a and C3b by the C3 convertase (286). C3b 
can then be deposited onto the surface of pathogens or infected cells to facilitate 
lysis, neutralization, or phagocytosis. Since complement activation occurs through 
an amplifying cascade of proteolytic events, cellular regulators of complement 
activation (RCA) proteins keep this pathway in check to avoid hyperinflammatory 
responses (286).  KSHV ORF4 encodes a structural and functional homolog to 
cellular RCA proteins called the KSHV complement control protein (KCP) (287, 288). 
KCP is able to prevent cleavage of C3 through accelerating the decay of the C3 
convertase, by acting as an inhibitory cofactor to inactivate C3b and downstream 
complement molecules, and by preventing deposition of C3b onto target surfaces 
(289, 290). By evading the complement pathway, the virus is able to avoid 
neutralization of extracellular virions by complement deposition, decrease the 
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elimination of infected cells, and reduce the acquisition of viral antigens by 
phagocytes and APCs to inhibit the adaptive immune response. 
 As discussed in the adaptive immune evasion section, KSHV downregulates 
MHC-I expression on APCs. NK cells are designed to sense and kill cells displaying 
abnormal MHC-I levels through their leukocyte Ig-like receptor 1 (LIR1) and killer 
inhibitory receptor (KIR), which recognize endogenous MHC-I molecules on cells. To 
prevent the elimination of infected cells with reduced MHC-I, KSHV utilizes multiple 
mechanisms to inhibit NK cell function. In addition to downregulating MHC-I, KSHV 
K5 also downregulates surface expression of ICAM-1 and B7-2 (CD86) to avoid NK-
mediated cell cytotoxicity (240, 242, 250). NK cell killing requires activation of the 
NKG2D and NKp80 receptors. As mentioned earlier, the KSHV miRNA miR-K12-7 
targets the NKG2D ligand MHC class I-related chain B (MICB) 3’UTR. This results in 
decreased expression of this NKG2D ligand and effectively reduces NK cell killing 
ability (131). K5 also decreases the surface expression MICB and another NKG2D 
ligand, MICA, as well as the NKp80 ligand activation-induced C type lectin (AICL) 
(291). In these ways, KSHV has cleverly devised mechanisms to not only reduce 
activation of the adaptive immune system by downregulating MHC-I, but also to 
avoid the detrimental side effects of abnormal MHC-I levels on infected cells.  
 
CONCLUSIONS 
KSHV expresses a diverse repertoire of proteins and small RNAs that aid the 
virus in establishing a lifelong infection in the host. Many of these viral components 
inadvertently cause transformation of host cells, linking KSHV with the development 
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of several human malignancies. These cancers pose a large threat to global public 
health, particularly in areas that are still struggling with limited treatment options for 
HIV infection. Two decades of KSHV research has elucidated many of the 
mechanisms by which KSHV is able to establish and maintain infection in the host 
and initiate tumorigenesis; however, despite this extensive research, there are still 
aspects of viral infection and transformation that are not well understood. Further 
elucidating the unique mechanisms that KSHV uses to persist so successfully in the 
host will hopefully uncover novel therapeutic targets for the treatment of KSHV 
disease. 
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CHAPTER 2: MODULATION OF KSHV VIL-6 FUNCTION BY HYPOXIA 
UPREGULATED PROTEIN 13  
 
OVERVIEW 
Kaposi’s sarcoma-associated herpesvirus (KSHV, also called human 
herpesvirus 8) is linked to the development of Kaposi’s sarcoma (KS), primary 
effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD). KSHV 
expresses several proteins that modulate host cell signaling and deregulate cell 
growth. One of these proteins is viral interleukin-6 (vIL-6) which is a homolog of 
human interleukin-6. vIL-6 is able to prevent apoptosis and promote pro-
inflammatory signaling, angiogenesis, and cell proliferation. Although it can be 
secreted, vIL-6 is mainly an intracellular protein that is retained in the endoplasmic 
reticulum (ER). We performed affinity purification and mass spectrometry to identify 
novel vIL-6 binding partners and found that the cellular ER chaperone hypoxia 
upregulated protein 1 (HYOU1) interacts with vIL-6. Immunohistochemical staining 
revealed that both PEL and KS tumor tissues express significant amounts of 
HYOU1. We also show that HYOU1 increases endogenous vIL-6 protein levels and 
that HYOU1 facilitates vIL-6-induced JAK/STAT signaling, migration, and survival in 
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endothelial cells. Furthermore, our data suggest that HYOU1 also modulates vIL-6’s 
ability to induce CCL2, a chemokine involved in cell migration. Finally, we 
investigated the impact of HYOU1 on cellular human IL-6 (hIL-6) signaling. 
Collectively, our data indicate that HYOU1 is important for vIL-6 function and may 
play a role in the pathogenesis of KSHV-associated cancers. 
 
INTRODUCTION 
Kaposi’s sarcoma-associated herpesvirus (KSHV; Human Herpesvirus 8) is 
the causative agent of several human malignancies including Kaposi’s sarcoma 
(KS), primary effusion lymphoma (PEL), and multicentric Castleman’s disease 
(MCD) (3-6). These malignancies often occur in the context of immunosuppression, 
and as a result KSHV-associated malignancies have increased in incidence since 
the onset of the AIDS epidemic (2). KSHV is a member of the gamma-herpesvirus 
subfamily and has a double-stranded DNA genome that expresses over eighty open 
reading frames (ORFs) (40). KSHV infection usually exists in a latent state in which 
a small subset of the viral genome is expressed. When the virus undergoes lytic 
reactivation, all viral genes are expressed and progeny virions are produced.  
It is thought that several latent and lytic genes contribute to modulation of 
host cell signaling to induce tumorigenesis. One of these genes is ORF K2 which 
encodes a viral homolog of human interleukin-6 (hIL-6) called viral interleukin-6 (vIL-
6) (195-197). vIL-6 shares 25% identity and 63% similarity to hIL-6 at the amino acid 
level. vIL-6 is expressed at low levels in latently infected PEL and is highly 
upregulated upon lytic reactivation (143, 144, 207). All KSHV-associated 
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malignancies have detectable vIL-6 levels (55, 64, 194). vIL-6 expression transforms 
NIH3T3 cells, and vIL-6-expressing cells injected into mice form larger tumors as 
compared to control cells (61). Additionally, transgenic mice engineered to express 
vIL-6 under the MHC Class I promoter display a phenotype reminiscent of KSHV-
associated plasmablastic MCD that is also dependent on mouse IL-6 expression 
(213). vIL-6 drives production of hIL-6 (200) and vascular endothelial growth factor 
(VEGF) (61) and can promote angiogenesis (211). Importantly, vIL-6 activates 
similar signaling pathways to the human cytokine, including the JAK/STAT, MAPK, 
and PI3K pathways (62, 198, 199).  
vIL-6 differs from hIL-6 in several ways: hIL-6 must bind the IL-6 receptor (IL-
6R, gp80) before activation of the gp130 signal transducer subunit, whereas vIL-6 
can directly bind gp130 to induce signaling (201-203); however, involvement of gp80 
can enhance vIL-6 signaling (205). Another difference is that hIL-6 is rapidly 
secreted from cells whereas vIL-6 is primarily retained within the endoplasmic 
reticulum (ER) (206, 207). In this compartment, vIL-6 binds gp130 in a tetrameric 
complex to induce intracellular signaling (207). The cellular ER protein, calnexin, has 
been shown to interact with vIL-6 to stabilize vIL-6 folding and maintain its 
intracellular distribution (142). The ER transmembrane protein vitamin K epoxide 
reductase complex subunit 1 variant 2 (VKORC1v2) was recently identified as an 
additional intracellular binding partner of vIL-6 (292, 293). vIL-6 binds to 
VKORC1v2’s C terminus which is present in the ER lumen, but data suggest that 
this binding domain is not responsible for retention of vIL-6 in the ER. 
Overexpression of VKORC1v2’s vIL-6 binding domain or depletion of VKORC1v2 
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abrogates vIL-6’s pro-growth phenotype in PEL cells independently of gp130 
signaling (292). Furthermore, it was found that vIL-6 promotes PEL cell survival by 
suppressing the pro-apoptotic properties of the VKORC1v2 binding partner, 
cathepsin D (294). This suggests that VKORC1v2 uses a mechanism independent 
of gp130 signaling to promote vIL-6 function and PEL cell survival.  
We performed affinity purification and mass spectrometry to identify novel 
binding partners of intracellular vIL-6. We found that a protein called hypoxia 
upregulated protein 1 (HYOU1; also called oxygen regulated protein 150 or 
ORP150) is able to bind vIL-6. HYOU1 is an ER resident chaperone protein that is a 
member of the heat shock and ER stress protein families (295). HYOU1 is 
expressed in many different cell types and can be upregulated by various cellular 
conditions including hypoxia and ER stress (295, 296). Furthermore, HYOU1 is 
upregulated in some human cancers including head and neck and breast cancer 
(297, 298). The HYOU1 transcript was originally cloned from astrocytes under 
hypoxic conditions (299), which makes it a relevant protein in KSHV biology since 
hypoxia plays a role in the KSHV lifecycle (300).  Previous work has indicated that 
HYOU1 can suppress hypoxia-induced cell death (301) and induce angiogenesis by 
facilitating VEGF processing (302).   
We found that HYOU1’s interaction with vIL-6 is important for vIL-6-induced 
intracellular STAT3 signaling and vIL-6 expression in PEL cells. Furthermore, we 
show that HYOU1 is required for several vIL-6 biological functions including 
promotion of endothelial cell survival and migration. We found that vIL-6 increases 
extracellular levels of chemokine (C-C motif) ligand 2 (CCL2, also called monocyte 
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chemoattractant protein 1 or MCP1) in a HYOU1-dependent manner. CCL2 is 
implicated in the migration and metastasis of tumor cells and the extravasation of 
immune cells (303, 304). Finally, we investigated the impact of HYOU1 on cellular 
human IL-6 (hIL-6) signaling. Our results suggest that by modulating vIL-6 function 
HYOU1 may contribute to KSHV-associated tumorigenesis, making HYOU1 an 
attractive target for the treatment of KSHV-associated malignancies. 
 
METHODS 
Cell Culture and Generation of Stable Cell Lines 
 Human embryonic kidney (HEK) 293 and HEK293T cells were cultured in 
Dulbecco’s modified Eagle’s medium (Corning). BCBL1 PEL cells were cultured in 
RPMI 1640 medium (Corning) containing 0.05 mM β-mercaptoethanol. TREx BCBL1 
and TREx BCBL1-RTA PEL cells (305) were cultured in RPMI 1640 medium 
(Corning) containing Tet System Approved FBS (Clontech) and 20 μg/mL 
hygromycin B (Roche). hTERT-immortalized human umbilical vein endothelial cells 
(hTERT-HUVEC) were cultured in EBM-2 (Lonza) with the EBM-2 bullet supplement 
(Lonza) as described (178). All media were additionally supplemented with 10% heat 
inactivated fetal bovine serum (FBS), 1% penicillin-streptomycin (PS), and 1% L-
glutamine. Charcoal filtered FBS was obtained from Life Technologies. Cells were 
transfected with XtremeGene HP transfection reagent (Roche) at a ratio of 2 µL 
XtremeGene: 1µg plasmid DNA as per the manufacturer’s protocol. Cells were 
transfected with 50-100 nM siRNA utilizing Lipofectamine RNAimax (Invitrogen) as 
per the manufacturer’s protocol. For lentiviral transductions, adherent cells were 
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grown to 70% confluence and inoculated with lentivirus in the presence of 8 μg/mL 
polybrene. Spinoculation was used for PEL cell transductions as previously 
described (223). All transfections and transductions were incubated for 48-72 hours 
to allow for protein expression or knockdown. hTERT-HUVEC cells and HEK293 
cells stably expressing empty vector or vIL-6 were generated by lentiviral 
transduction. HEK293 cells stably expressing a non-targeting shRNA or a HYOU1 
targeting shRNA plasmid (described below) were also generated by lentiviral 
transduction. For all stable cells, media were changed 24 hours post-transduction 
and the puromycin concentration was increased from 0.1 μg/mL to a final 
concentration of 0.5 μg/mLfor hTERT-HUVEC and 1.0 μg/mL for HEK293 cells over 
2 weeks.  
Plasmids, Lentiviral vectors, shRNAs, and siRNAs 
The pcDNA3.1-vIL-6-His clone was a kind gift from Yuan Chang and Patrick 
Moore. A C-terminal FLAG tag was added to vIL-6 and cloned into the pcDNA3.1 
eukaryotic expression vector (Invitrogen). pSG5-based eukaryotic expression 
vectors for untagged hIL-6 and hIL-6 with an ER-targeting motif containing KDEL 
and additional sequences (306) were a kind gift from John Nicholas and were 
previously described (207). The non-targeting control (NTC) siRNA duplex was 
purchased from Dharmacon (D001810-01) and the HYOU1-targeting siRNA duplex 
was designed and purchased from Invitrogen (NM_001130991_stealth_455) utilizing 
the Block-iT RNAi Designer as previously described (307). Plasmids for the pLKO.1 
non-targeting control (NTC) shRNA and a HYOU1-targeting shRNA 
(TRCN0000029220) were purchased from Sigma and used to generate lentivirus. 
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FLAG-tagged vIL-6 was cloned into the lentiviral vector pSuper-CMV puro 
(Invitrogen). All lentiviruses were produced using the ViraPower Lentiviral 
Expression System (Invitrogen) as per the manufacturer’s instructions. 
Mass Spectrometry, Immunoprecipitations, and Western Blots 
Twenty million 293T cells were transfected with pcDNA3 or vIL-6 expression 
vectors for 48 hours. Cells were harvested on ice in NP-40 lysis buffer (0.1% NP-40, 
150 mM NaCl, 50 mM Tris HCl pH 8.0, 30 mM β-glycerophosphate, 50 mM NaF, 1 
mM Na3VO4, 1 Roche protease inhibitor tablet per 50 mL) followed by one freeze-
thaw cycle. Samples were clarified by centrifugation at 16 000 x g for 10 minutes 
and protein content was determined by Bradford assay (Bio-Rad). Equal amounts of 
protein were loaded on FLAG antibody-conjugated beads (EZview Red ANTI-FLAG 
M2 Affinity Gel; Sigma) and rocked at 4oC overnight. Beads were washed twice with 
lysis buffer followed by 2 washes with 50 mM NH4HCO3. Samples were eluted with 
3x FLAG peptide (Sigma) diluted in 50 mM NH4HCO3 and 0.1% PPS Silent 
Surfactant (Protein Discovery). Samples were treated with 5 mM dithiothreitol at 
60oC for 15 minutes. Proteins were trypsinized using the FASP protein digestion 
protocol (Protein Discovery) and tryptic peptides were separated by a nanoAquity 
UPLC system (Waters Corp.) with a 2-cm trapping column and a self-packed 25-cm 
analytical column (75-μm ID, Michrom Magic C18 beads of 5.0-μm particle size, 100-
Å pore size) at room temperature. The flow rate was 350 nl/min over a gradient of 
1% buffer B (0.1% formic acid in acetonitrile) to 35% buffer B in 200 min. Full mass 
spectrum scan [300 to 2000 mass/charge ratio (m/z)] was acquired in an LTQ-
Orbitrap Velos mass spectrometer (Thermo Scientific) at 60 000 resolution setting; 
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data-dependent MS2 spectra were acquired by collision-induced dissociation with 
the 15 most intense ions. All raw data were searched with Sorcerer-SEQUEST 
server (Sage-N Research) against the human UniProtKB/Swiss-Prot sequence 
database. Search parameters used were a precursor mass between 400 and 4500 
atomic mass units (amu), up to 2 missed cleavages, a precursor-ion tolerance of 3 
amu, semi-tryptic digestion, a static carbamidomethyl cysteine modification, and 
variable methionine oxidation. False discovery rates (FDRs) were determined by 
ProteinProphet, and minimum protein probability cutoffs resulting in a 1% FDR were 
used.  
For HYOU1 immunoprecipitations, cell lysates containing equal amounts of 
protein were precleared by incubation with Protein A beads and normal rabbit IgG. 
Beads were pelleted and supernatants were incubated with 8 μL HYOU1 antibody or 
rabbit IgG for 5 hours prior to the addition of 50 μL Protein A beads overnight. Beads 
were pelleted and washed twice with lysis buffer and twice with cold TBS. Bound 
proteins were eluted by boiling in Laemmeli buffer for 5 minutes. For FLAG-vIL-6 
immunoprecipitation, HEK293 cells stably expressing empty vector or vIL-6 were 
transfected with 75 nM NTC or HYOU1-targeting siRNA for 72 hours. Equal amounts 
of cell lysates were precleared by Protein A beads and normal rabbit IgG then 
incubated with 50 μL FLAG antibody-conjugated beads overnight. Bound proteins 
were eluted with 3x FLAG peptide. All immunoprecipitation inputs and eluates were 
resolved on 10% SDS-PAGE gels and transferred to nitrocellulose membranes. 
Membranes were blocked with 5% non-fat dry milk in 1x TBS/0.1% Tween (TBST) 
followed by overnight incubation with primary antibody at 4oC. Blots were then 
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incubated with the appropriate HRP-conjugated secondary antibody for 1 hour at 
room temperature. Blots were developed with PicoWest chemiluminescent reagent 
(Thermo). Primary antibodies used were Flag (Bethyl, A190-101P), Actin (Santa 
Cruz, sc-1615), Tubulin (Cell Signaling, 9099), phospho-STAT3 Tyr705 (Cell 
Signaling, 9131), Total STAT3 (Cell Signaling, 4904), HYOU1 (Abcam, ab134944), 
human IL-6 (Abcam, ab32530), gp130 (Santa Cruz, sc-655), LANA (Advanced 
Biotechnologies (13-210-100), RTA (a gift from Ren Sun), K8.1 (Advanced 
Biotechnologies, 13-212-100), and vIL-6 (Advanced Biotechnologies, 13-214-050). 
Anti-rabbit, anti-mouse, and anti-rat (Cell Signaling) and anti-goat (Santa Cruz) 
horseradish peroxidase-conjugated secondary antibodies were used. Normal rabbit 
IgG (Santa Cruz, sc-2027) and Protein A beads (Santa Cruz sc-2003) were used for 
preclearing immunoprecipitation samples. 
Immunohistochemistry  
Immunohistochemical staining was carried out as described previously (308). 
PEL xenograft tumors were obtained from a previous study (308). Prepared sections 
of confirmed KSHV-positive KS lesions from specimen IDs 30035001 and 30035006 
were obtained from the AIDS and Cancer Specimen Resource (ACSR). For HYOU1 
staining, slides were deparaffinized and rehydrated then incubated in 3% H2O2 in 
10% methanol. Antigen retrieval was accomplished by boiling sections in 1 mM 
ethylenediaminetetraacetic acid (pH 8.0) for 10 minutes. Slides were incubated with 
blocking buffer (10% normal horse serum, 5% BSA, 0.3% Triton X-100) for 1 hour 
followed by overnight incubation with HYOU1 antibody (1:100) or blocking buffer as 
a negative control. Sections were washed and incubated with biotinylated goat anti-
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rabbit secondary antibody for 1 hour followed by signal amplification with the 
Vectastain ABC rabbit IgG kit (Vector labs). Sections were stained with 3, 3’-
diaminobenzidine (DAB) peroxide substrate according to the manufacturer’s protocol 
(Vector Labs). For LANA staining, antigen retrieval was accomplished by boiling 
sections in Retrievagen A pH 6.0 (BD Pharmingen). Slides were incubated in 
blocking buffer (1.5% rabbit serum, 1% BSA, 0.1% Triton X100, 0.05% Tween-20, 
0.1% gelatin from cold water fish skin in 1x PBS) for 1 hour followed by overnight 
incubation with LANA antibody diluted 1:100 in antibody buffer (1% BSA, 0.1% 
Triton X-100, 0.1% gelatin from cold water fish skin in 1x PBS) or plain antibody 
buffer for the negative control. Sections were washed and incubated with 
biotinylated rabbit anti-rat secondary antibody for 30 minutes followed by signal 
amplification with the Vectastain ABC rat IgG kit. Slides were stained with NovaRed 
substrate according to the manufacturer’s protocol (Vector Labs). All slides were 
counterstained with hematoxylin . Slides were imaged using a Leica DM LA 
histology microscope with 20x/0.25 numeric aperture (NA) and 40×/0.75 NA 
objectives. 
 Endothelial Cell Assays 
Scratch assay: Stable empty vector- or vIL-6-expressing hTERT-HUVEC 
were plated at 1.5x105 cells/well of a 6 well dish. The following day, cells were 
transduced with lentivirus expressing NTC or HYOU1-targeting shRNA as described. 
Media were changed after 24 hours, and 48 hours post-transduction cells were 
serum-starved overnight with plain EBM-2. The monolayer was scratched with a P10 
pipet tip, and a Nikon Eclipse Ti inverted microscope was used to obtain brightfield 
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images of the cells at 40x or 100x magnification at the indicated timepoints. ImageJ 
software (NIH) was used to quantify the area of each scratch over time. 
CCL2 ELISA: Stable empty vector- or vIL-6-expressing hTERT-HUVEC were 
plated at 1.2x105 cells/well of a 6 well dish. The following day, cells were transfected 
with 100 nM NTC or HYOU1-targeting siRNA as described. Seventy-two hours post-
transfection, media were replaced with serum-free EBM-2 without supplements for 
48 hours. Following harvest, the media were cleared of debris by centrifugation and 
a CCL2 ELISA was carried out as per the manufacturer’s protocol (Life 
Technologies). Samples were all run in triplicate. Absorbance was read at 450 nm 
on a VersaMax tunable microplate reader (Molecular Devices) and a standard curve 
was generated using a best fit power trendline in Microsoft Excel. Error bars 
represent the standard deviation and CCL2 concentrations were compared using a 
two-tailed Student’s t test with p < 0.05 considered significant. Results are 
representative of at least 3 experiments.   
Survival Assay: Stable empty vector- or vIL-6-expressing hTERT-HUVEC 
were plated at 1.2x105 cells/well of a 6 well dish. The following day, cells were 
transfected with 100 nM NTC or HYOU1-targeting siRNA as described. Seventy-two 
hours post-transfection, media were replaced with serum-free EBM-2 without 
supplements and a Nikon Eclipse Ti inverted microscope was used to obtain 
brightfield images of the cells at 40x or 100x magnification at the indicated 
timepoints. Media were replaced with fresh serum-free media before each timepoint 
to remove dead cell debris.  
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Cytotoxicity Assay: Three thousand cells/well of stable empty vector- or vIL-6-
expressing hTERT-HUVEC were plated and transfected in two white walled 96 well 
plates using RNAimax and 100 nM NTC or HYOU1-targeting siRNA according to the 
manufacturer’s protocol for reverse transfection (Invitrogen). Samples were 
transfected in triplicate. Three days post-transfection, one plate was used to 
measure baseline cytotoxicity at day 0 using the CytoTox Glo kit (Promega) as per 
the manufacturer’s instructions with a FLUOstar Optima luminometer (BMG 
Labtech). The media of the second plate was replaced with serum-free EBM-2 
without supplements for 6 days followed by a second cytotoxicity assay. The 
percentage of dead cells at each timepoint was calculated from the raw data. Data is 
shown as a fold change in cell death which was calculated by dividing the 
percentage of dead cells at day 6 by the percentage at day 0. Error bars represent 
the standard deviation of the mean, and a one way ANOVA with Tukey’s post-hoc 
test was used to compare all samples with a p value < 0.05 considered significant.  
 
RESULTS 
Identification of HYOU1 as a vIL-6 Binding Partner 
The biological effects of extracellular vIL-6 have been extensively studied (61, 
62, 195, 198-200) but less is known about vIL-6’s interactions with intracellular 
proteins. We sought to identify additional cellular proteins that bind to vIL-6 and 
impact its function. We cloned vIL-6 with an N-terminal FLAG tag into the pcDNA3.1 
vector (pcDNA3.1-vIL-6), and transfected pcDNA3.1 empty vector or pcDNA3.1-vIL-
6 into HEK293T cells. Cells were harvested and subjected to an immunoprecipitation 
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with FLAG antibody-conjugated beads. vIL-6-bound proteins were eluted with 3x 
FLAG peptide. A fraction of the elution was subjected to SDS-PAGE and 
subsequent silver staining or Western blotting for vIL-6 to ensure successful vIL-6 
expression and pull down (Figure 2.1 A). The vIL-6 concentration in the lysate was 
high enough that dimerization of the vIL-6 protein was evident by Western blot 
(Figure 2.1 A, right panel). The remainder of the eluted samples were digested with 
trypsin and analyzed by shotgun mass spectrometry (309). Proteins with peptide 
counts that were higher in the vIL-6-FLAG sample than the empty vector sample 
were identified as potential vIL-6 binding partners (Figure 2.1 B). Consistent with 
previous findings (142), over 40 unique calnexin peptides and 9 unique gp130 
peptides were identified in the vIL-6 sample. The vIL-6 sample also had 9 unique 
peptides identified for the protein hypoxia upregulated protein 1 (HYOU1; ORP150) 
while no HYOU1 peptides were identified in the empty vector control. 
To confirm that HYOU1 interacts with vIL-6, we again transfected HE293T 
cells with empty vector or FLAG-tagged vIL-6 constructs. Lysates from these cells 
were immunoprecipitated with HYOU1 antibody or rabbit IgG as a control, and 
bound proteins were eluted by boiling in Laemmli buffer. Eluates and input samples 
were resolved on an SDS-PAGE gel and analyzed by Western blotting. As seen in 
Figure 2.1 C, vIL-6 coimmunoprecipitated with HYOU1. To determine if vIL-6 
interacts with HYOU1 in a more relevant cell type, BCBL1 PEL cells were 
transduced with lentivirus expressing empty vector or FLAG-tagged vIL-6 and 
lysates were harvested 48 hours later. The FLAG-tagged vIL-6 was 
immunoprecipitated by FLAG antibody-conjugated beads and bound proteins were 
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eluted with FLAG peptide. Our data again showed that HYOU1 
coimmunoprecipitated with vIL-6, suggesting that there is a bona fide interaction 
between HYOU1 and vIL-6 in multiple cell types.  
 
Figure 2.1: vIL-6 binds the ER chaperone protein hypoxia upregulated protein 1 
(HYOU1). (A) HEK293T cells were transfected with empty vector (EV) or FLAG-tagged vIL-6 
and lysates were harvested for a FLAG bead immunoprecipitation. Portions of the bead 
eluates were analyzed by SDS-PAGE and subsequent silver staining (left panel; M is the 
size marker) or Western blot for vIL-6 (right panel). An asterisk denotes the expected 
location of HYOU1. (B) HYOU1, Calnexin, and gp130 were identified as binding partners of 
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vIL-6 by mass spectrometry. (C) HEK293T cells were transfected with empty vector or vIL-6 
constructs and lysates were harvested and immunoprecipitated with HYOU1 or rabbit IgG 
control antibody. Bound proteins were eluted with Laemmli buffer. Samples were analyzed 
by SDS-PAGE and Western blotting for the indicated proteins. (D) BCBL1 PEL cells were 
transduced with lentivirus expressing empty vector or FLAG-tagged vIL-6. Lysates were 
immunoprecipitated with FLAG beads and eluates and inputs were analyzed by SDS-PAGE 
and Western blotting for the indicated proteins. 
 
To determine if HYOU1 is expressed in tumors associated with KSHV 
infection, sections of BC-1 PEL tumors grown in immunodeficient mice (308) and 
human KS sections were stained for HYOU1 using DAB peroxide substrate. 
Matched tumor sections were also stained for LANA to confirm KSHV infection. 
HYOU1 and LANA staining were observed in both PEL xenografts and in KS lesions 
(Figures 2.2 A and 2.2 B). In the PEL xenografts in particular, HYOU1 displayed 
distinct perinuclear staining which is consistent with its ER localization (Figure 2.2A). 
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Figure 2.2: HYOU1 is expressed in tissue from KSHV-associated tumors. (A) 
Immunohistochemical staining for HYOU1 and LANA on BC-1 PEL xenograft sections. The 
control received no primary antibody. (B) Immunohistochemical staining for HYOU1 and 
LANA on sections of human KS lesions. The control received no primary antibody. 
 
HYOU1 Increases vIL-6 Levels 
HYOU1 is an ER chaperone protein (295) so we sought to determine if its 
interaction with vIL-6 influences endogenous vIL-6 protein levels. BCBL1 PEL cells 
were transduced with lentivirus expressing a non-targeting control (NTC) shRNA or 
a HYOU1-targeting shRNA. Three days post-transduction, cells were treated with 
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DMSO to maintain latency or 25 ng/mL 12-O-Tetradecanoylphorbol 13-acetate 
(TPA) to induce lytic reactivation for 24 hours. Cell lysates and media were 
harvested and analyzed by SDS-PAGE and Western blot. High levels of HYOU1 
knockdown were achieved with the HYOU1-targeting shRNA, and as expected, vIL-
6 levels were higher overall in lytic samples since vIL-6 is induced during lytic 
reactivation (144) (Figure 2.3 A). We found that HYOU1 knockdown decreased 
endogenous vIL-6 protein levels in both lytic and latent BCBL1 cells (Figure 2.3 A). 
Additionally, HYOU1 knockdown decreased levels of secreted vIL-6 during 
reactivation. While this is likely due to the increased levels of intracellular vIL-6 when 
HYOU1 is expressed, we cannot rule out the possibility that HYOU1 may also 
promote the secretion of vIL-6.  
We also performed this experiment using TREx BCBL1 and TREx BCBL1-
RTA PEL lines that express doxycycline-inducible empty vector and doxycycline-
inducible RTA, respectively (305). The two TREx BCBL1 cell lines were transduced 
with lentivirus expressing a NTC or a HYOU1-targeting shRNA. After 72 hours, cells 
received 1 μg/mL doxycycline for 24 hours to maintain latency in the TREx BCBL1 
cells and induce lytic replication in the TREx BCBL1-RTA cells. Cell lysate and 
media were harvested and analyzed by SDS-PAGE and Western blotting for the 
indicated proteins (Figure 2.3 B). Similar to the results seen in BCBL1 PEL cells, 
knockdown of HYOU1 in both latent TREx BCBL1 and lytic TREx BCBL1-RTA cells 
reduced levels of intracellular and extracellular vIL-6. Conversely, levels of LANA did 
not significantly change with HYOU1 knockdown in both the latent and lytic cells. We 
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also examined the levels of the lytic proteins RTA and K8.1 in the reactivated cells, 
and found that HYOU1 knockdown did not impact the levels of these lytic proteins.  
 
Figure 2.3: HYOU1 increases endogenous vIL-6 levels. (A) BCBL1 PEL cells were 
transduced with lentivirus expressing a non-targeting control (NTC) or HYOU1-targeting 
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shRNA. Three days later, cells were treated with DMSO or 25 ng/mL TPA to induce 
reactivation for 24 hours. Lysates and media were collected and analyzed by SDS-PAGE 
and Western blot for the indicated proteins. (B) TREx BCBL1 and TREx BCBL1-RTA PEL 
cells expressing doxycycline-inducible empty vector or RTA, respectively, were transduced 
with lentivirus expressing a NTC or HYOU1-targeting shRNA. Three days post-transduction, 
1 μg/mL doxycycline was added for 24 hours. Lysates and media were harvested and 
analyzed by SDS-PAGE and Western blot for the indicated proteins. (C) HEK293 stably 
knocked down for HYOU1 (left panel) or HEK293 first transfected with NTC or HYOU1-
targeting siRNA (right panel) were then transfected with a titration of FLAG-tagged vIL-6 
plasmid for 48 hours. Lysates were harvested and analyzed by SDS-PAGE and Western 
blot for the indicated proteins. 
 
To further investigate if HYOU1 knockdown impacts levels of vIL-6, we used 
HEK293 cells stably expressing a NTC or a HYOU1-targeting shRNA. These cells 
were then transfected with a titration of FLAG-tagged vIL-6 plasmid for 48 hours. We 
also performed a similar experiment by transiently transfecting HEK293 cells with 
NTC or HYOU1-targeting siRNA for 24 hours followed by transfection with a titration 
of FLAG-tagged vIL-6 plasmid for 48 hours. Lysates from both of these experiments 
were harvested and analyzed by Western blot (Figure 2.3 C). In both of these 
experiments, knockdown of HYOU1 prior to expression of FLAG-tagged vIL-6 
resulted in a reduction in vIL-6 expression, as compared to cells that expressed 
endogenous levels of HYOU1. These results closely match the phenotype we see in 
PEL cells endogenously expressing vIL-6 (Figure 2.3 A and 2.3 B). Interestingly, we 
find that when FLAG-tagged vIL-6 is expressed prior to knockdown of HYOU1, vIL-6 
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levels do not appear to be significantly changed by knockdown of HYOU1 (Figures 
2.4, 2.5 C, 2.6 B and 2.7 B).  For subsequent experiments, we chose to overexpress 
FLAG-tagged vIL-6 before knocking down HYOU1 to keep the amount of vIL-6 the 
same and eliminate differences in vIL-6 levels as a variable contributing to the 
observed results. This approach allowed us to determine if HYOU1 actually affects 
vIL-6 function as opposed to simply affecting vIL-6 protein levels as a mechanism of 
action.  
HYOU1 Facilitates vIL-6-Dependent STAT Signaling 
Following activation of gp130, STAT3 becomes phosphorylated at Y705. This 
causes STAT3 to dimerize and relocate to the nucleus where it upregulates IL-6-
responsive proinflammatory genes. Others have shown that vIL-6 induces STAT3 
Y705 phosphorylation through activation of gp130 (142, 199). To determine if 
HYOU1’s interaction with vIL-6 is involved in the induction of this signaling cascade, 
HEK293 cells were transfected with empty vector or FLAG-tagged vIL-6 plasmid 
followed by transfection of a NTC or HYOU1-targeting siRNA 24 hours later. Twenty-
four hours after the siRNA transfection, media were replaced with serum-free media 
for another 24 hours. Lysates were harvested and analyzed by SDS-PAGE and 
Western blotting. Compared to cells expressing empty vector, vIL-6 increased 
STAT3 Y705 phosphorylation in the presence of HYOU1; however, knockdown of 
HYOU1 diminished this phosphorylation event (Figure 2.4 A). We generated hTERT-
HUVEC (178) stably expressing empty vector or FLAG-tagged vIL-6 and transfected 
these cells with NTC or HYOU1-targeting siRNA for 3 days. These cells were treated 
with plain EBM-2 media containing 2% charcoal-filtered FBS for 24 hours prior to 
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harvest to eliminate background levels of STAT3 phosphorylation. Lysates from the 
hTERT-HUVEC showed a similar trend to HEK293 cells for STAT3 phosphorylation 
(Figure 2.4 B). This suggests that HYOU1 is involved in enhancing vIL-6-induced 
activation of the JAK/STAT signaling pathway in multiple cell types.  
 
Figure 4: HYOU1 enhances vIL-6-induced STAT3 signaling. (A) HEK293 cells were 
transfected with empty vector (EV) or FLAG-tagged vIL-6 plasmids followed by a 
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transfection with non-targeting control (NTC) or HYOU1-targeting siRNA 24 hours later. 
Twenty-four hours post-siRNA transfection, cells were serum starved for another 24 hours. 
Lysates were harvested and analyzed by SDS-PAGE and Western blotting for the indicated 
proteins. (B) hTERT-HUVEC stably expressing EV or FLAG-tagged vIL-6 were transfected 
with NTC or HYOU1-targeting siRNA for 3 days. Media were replaced with plain EBM-2 with 
2% charcoal filtered FBS for 24 hours. Lysates were harvested and analyzed by SDS-PAGE 
and Western blotting. (C) HEK293 stably expressing EV or FLAG-tagged vIL-6 were 
transfected with 75 nM NTC or HYOU1 siRNA for 3 days. Lysates were harvested and 
subjected to a FLAG immunoprecipitation overnight. Bound proteins were eluted with 3x 
FLAG peptide and eluates and input samples were analyzed by SDS-PAGE and Western 
blotting for the indicated proteins. 
 
Since vIL-6 can bind ER-embedded gp130 to initiate JAK/STAT signaling 
(207), we hypothesized that HYOU1 may facilitate vIL-6-induced STAT3 
phosphorylation by promoting vIL-6’s interaction with gp130. To test this, we used 
HEK293 cells stably expressing an empty vector or FLAG-tagged vIL-6. Cells were 
transfected with 75 nM of a NTC or HYOU1-targeting siRNA for 72 hours. Lysates 
were harvested and subjected to an immunoprecipitation with FLAG beads to pull 
down vIL-6. Bound proteins were eluted with FLAG peptide and eluates and input 
samples were analyzed by SDS-PAGE and Western blotting.  We found that gp130 
coimmunoprecipitated with vIL-6 as expected, but knockdown of HYOU1 
consistently reduced this interaction (Figure 2.4 C). This suggests that HYOU1 
promotes the vIL-6-gp130 interaction, so this may be one mechanism by which 
HYOU1 facilitates vIL-6-mediated STAT signaling.   
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HYOU1 is Essential for vIL-6-Induced Endothelial Cell Migration  
To further understand the impact of HYOU1 on vIL-6 activity, we developed 
biological assays for vIL-6 function in endothelial cells. KS is a cancer of endothelial 
cell origin, and vIL-6 can be detected in patients with this malignancy (194).  
Therefore, endothelial cells are a relevant model to investigate vIL-6 function. We 
first investigated if vIL-6 can influence endothelial cell migration in a scratch assay. 
Equivalent numbers of hTERT-HUVEC stably expressing empty vector or FLAG-
tagged vIL-6 were plated as a confluent monolayer and serum starved overnight 
before scratching the monolayer with a P10 pipet tip. The scratch was monitored at 
various timepoints utilizing brightfield microscopy on a Nikon Eclipse Ti inverted 
microscope. Cells expressing vIL-6 were able to close the scratch faster than cells 
expressing empty vector (Figure 2.5 A). The influence of vIL-6 expression on 
endothelial cell migration has not been previously studied, so this data represents a 
novel biological function for vIL-6. 
We extended this assay to study the effect of HYOU1 on vIL-6-induced 
endothelial cell migration. hTERT-HUVEC stably expressing empty vector or FLAG-
tagged vIL-6 were transduced with lentivirus expressing a NTC or HYOU1-targeting 
shRNA. Two days post-transduction, cells were serum starved overnight prior to 
scratching the monolayer. Again, when HYOU1 was expressed normally the vIL-6-
expressing cells closed the scratch more rapidly than the empty vector-expressing 
cells (Figure 2.5 B). However, vIL-6-expressing cells knocked down for HYOU1 were 
unable to close the gap, similar to the empty vector-expressing cells (Figure 2.5 B). 
The area of each scratch was quantified with ImageJ software (Figure 2.5 C). 
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Lysates were harvested from these cells and subjected to SDS-PAGE and Western 
blotting to confirm HYOU1 knockdown and vIL-6 expression (Figure 2.5 D). These 
data suggest that HYOU1 is critical for vIL-6-induced migration of endothelial cells.  
 
 
Figure 2.5: HYOU1 facilitates vIL-6-induced migration of endothelial cells. (A) hTERT-
HUVEC cells stably expressing empty vector (EV) or FLAG-tagged vIL-6 were serum 
starved overnight and scratched with a P10 pipet. Scratch closure was monitored at 0, 4, 8, 
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12, and 24h by brightfield microscopy at 100x magnification using a Nikon Eclipse Ti 
inverted microscope. (B) hTERT-HUVEC cells stably expressing EV or FLAG-tagged vIL-6 
were transduced with lentivirus expressing a non-targeting control (NTC) or HYOU1-
targeting shRNA. Cells were serum starved overnight and scratched with a P10 pipet tip and 
monitored for scratch closure at 0, 6, 12, and 24h at 40x magnification. (C) Quantification of 
the area of each scratch pictured in figure 5B normalized to the 0hr timepoint. (D) Lysates 
from the cells described in panel B were harvested at the 24h timepoint and analyzed by 
SDS-PAGE and Western blot to confirm efficient HYOU1 knockdown and vIL-6 expression. 
(E) hTERT-HUVEC cells stably expressing EV or FLAG-tagged vIL-6 were transfected with 
50 nM NTC or HYOU1-targeting siRNA for 3 days followed by serum starvation for 48 hours. 
Supernatants were collected and a CCL2 ELISA was performed with each sample tested in 
triplicate. Absorbance was read at 450 nm and a standard curve was generated using a best 
fit power trendline in Microsoft Excel. The concentrations of the samples were calculated 
and error bars represent standard deviation of the triplicates. A two-tailed Student’s t test 
was used to compare the sample concentrations with a p value < 0.05 considered 
significant. Results are representative of at least 3 experiments. 
 
To elucidate the mechanism by which vIL-6 induces endothelial cell migration, 
we investigated if vIL-6 affects the levels of chemokine (C-C motif) ligand 2 (CCL2, 
also called monocyte chemoattractant protein 1 or MCP1) since this chemokine is 
associated with tumor cell migration and metastasis and increased vascular 
permeability (303, 304). We transfected hTERT-HUVEC stably expressing an empty 
vector or FLAG-tagged vIL-6 with 100 nM of NTC or HYOU1-targeting siRNA for 72 
hours followed by serum starvation for 48 hours. We performed a CCL2 ELISA on 
61 
supernatants from these cells and found that vIL-6 expression increases the level of 
extracellular CCL2 as compared to the empty vector (Figure 2.5 E). Interestingly, 
knockdown of HYOU1 in vIL-6 cells caused the CCL2 level to decrease 
substantially, although the level of CCL2 in this sample was still higher than the level 
seen in hTERT-HUVEC expressing empty vector (Figure 2.5 E). This suggests that 
there may be other factors besides CCL2 that are involved in vIL-6-mediated cell 
migration.     
HYOU1 is Required for vIL-6-Mediated Endothelial Cell Survival 
We next investigated vIL-6’s role in endothelial cell survival in serum starved 
conditions. hTERT-HUVEC stably expressing empty vector or FLAG-tagged vIL-6 
were transfected with 100 nM of NTC or HYOU1-targeting siRNA. Seventy-two 
hours post-transfection, cells were serum starved and brightfield images were 
obtained at the indicated timepoints. vIL-6 expressing cells expressing HYOU1 
maintained normal morphology, remained adherent, and survived significantly longer 
in serum-free conditions than cells expressing empty vector (Figure 2.6 A). HYOU1 
knockdown had little impact on survival in cells expressing the empty vector. 
However, vIL-6-expressing cells with HYOU1 knockdown displayed significantly 
reduced survival as compared to vIL-6 cells expressing HYOU1 (Figure 2.6 A). 
Lysates from a duplicate set of samples were harvested for analysis by SDS-PAGE 
and Western blotting to ensure adequate HYOU1 knockdown and vIL-6 expression 
(Figure 2.6 B). 
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Figure 2.6: HYOU1 is required for vIL-6-induced endothelial cell survival in serum 
starved conditions. (A) hTERT-HUVEC stably expressing EV or FLAG-tagged vIL-6 were 
plated as a confluent monolayer and transfected with 100 nM non-targeting control (NTC) or 
HYOU1-targeting siRNA. Cells were serum starved 72 hours post-transfection and 
brightfield images at 100x magnification were taken at 0, 6, and 10 days post-starvation 
using a Nikon Eclipse Ti inverted microscope. Replicate samples were harvested 24 hours 
after starvation for analysis by SDS-PAGE and Western blot to confirm efficient vIL-6 
expression and HYOU1 knockdown (B). (C) hTERT-HUVEC stably expressing EV or FLAG-
tagged vIL-6 were reverse-transfected with 100 nM NTC or HYOU1-targeting siRNA in 
triplicate in two white-walled 96 well plates. Three days post-transfection, a CytoTox Glo 
(Promega) cytotoxicity assay was performed on the first plate and the percent of dead cells 
at Day 0 was calculated. The second plate was serum starved for 6 days followed by 
completion of a cytotoxicity assay used to calculate the percent of dead cells at Day 6. The 
graph represents a fold change in dead cells calculated by dividing the percentage of dead 
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cells at Day 6 by the percentage of dead cells at Day 0. Error bars represent standard 
deviation of the mean and p values were calculated using a one way ANOVA with Tukey’s 
post-hoc test to compare all values to each other, with a p value < 0.05 considered 
significant. This data is representative of 3 independent experiments. 
 
To quantify the effect of HYOU1 on vIL-6-induced survival, we performed a 
luminescence-based cytotoxicity assay. hTERT-HUVEC stably expressing empty 
vector or FLAG-tagged vIL-6 were reverse-transfected with 100 nM NTC or HYOU1 
siRNA in triplicate in two 96-well white-walled plates. Three days post-transfection, 
the cytotoxicity assay was performed on one plate (Day 0 reading). At this timepoint, 
the levels of cell death were comparable between all samples (data not shown). The 
second plate was serum starved for 6 days and another cytotoxicity assay was 
performed. The percentages of dead cells at day 0 and day 6 were calculated as per 
the manufacturer’s instructions. A fold change in dead cells was calculated by 
dividing the percentage of dead cells at day 6 by the percentage at day 0. Similar to 
trends seen in the serum starved survival assay (Figure 2.6 A), empty vector cells 
receiving NTC siRNA have a statistically significant increase in cell death after 6 
days of serum starvation as compared to vIL-6-expressing cells receiving the NTC 
siRNA (Figure 2.6 C). HYOU1 knockdown had little impact on the survival of cells 
expressing empty vector. However, knockdown of HYOU1 in vIL-6-expressing cells 
caused significantly higher levels of cell death after 6 days of serum starvation than 
vIL-6 cells expressing HYOU1 (Figure 2.6 C). Overall, these data suggest that 
HYOU1 is critical for vIL-6-mediated survival of serum starved endothelial cells. 
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HYOU1 Influences the Signaling of Human IL-6 
After confirming vIL-6’s interaction with HYOU1, we wanted to determine if 
hIL-6 can also interact with HYOU1. hIL-6 is rapidly secreted (206) so intracellular 
levels are typically undetectable by Western blot. hIL-6 constructs that were either 
wild type or tagged with an ER-targeting KDEL motif (207, 306) were transfected into 
HEK293 cells. Lysates were harvested and subjected to an immunoprecipitation with 
HYOU1 antibody followed by SDS-PAGE and Western blot analysis. We found that 
hIL-6-KDEL, but not wild-type hIL-6, coimmunoprecipitated with HYOU1 (Figure 2.7 
A). The fact that an immunoprecipitated band for wild type hIL-6 was not visible is 
not surprising since no wild type hIL-6 was identified in the input lysates, whereas 
high levels of hIL-6-KDEL were observed in the lysates (Figure 2.7 A). Therefore, 
HYOU1 can interact with hIL-6 only when this cytokine is retained in the ER. 
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Figure 2.7: HYOU1 interacts with and influences the signaling of hIL-6. (A) HEK293 
cells were transfected with empty vector (EV), vIL-6, wild type hIL-6, or hIL-6 with a KDEL 
motif (hIL-6-KDEL). Lysates were harvested and immunoprecipitated with a HYOU1 
antibody. Eluates were subjected to SDS-PAGE and Western blotting for the indicated 
proteins. Input lysates and media were analyzed for intracellular expression of HYOU1, vIL-
6, and hIL-6. (B) HEK293 cells were transfected with empty vector (EV), vIL-6, wild type hIL-
6, or hIL-6-KDEL for 24 hours followed by transfection with 100 nM of non-targeting or 
HYOU1-targeting siRNA for an additional 24 hours. Cells were serum starved overnight and 
66 
lysates and media were harvested for analysis by SDS-PAGE and Western blotting for the 
indicated proteins. 
 
Since we detected an interaction between HYOU1 and hIL-6-KDEL, we 
investigated if HYOU1 impacts wild type and KDEL-tagged hIL-6 signaling through 
the JAK/STAT pathway. HEK293 cells were transfected with empty vector, FLAG-
tagged vIL-6, wild type hIL-6, or hIL-6-KDEL for 24 hours followed by an additional 
transfection with either NTC or HYOU1-targeting siRNA. One day later cells were 
serum starved for 24 hours and lysates were harvested and subjected to SDS-PAGE 
and Western blotting. Expression of vIL-6 and wild type hIL-6 increased STAT3 
Y705 phosphorylation (Figure 2.7 B). hIL-6-KDEL also induced STAT3 
phosphorylation, which is likely due to leaky expression of hIL-6-KDEL into the 
media  in our experimental system (Figure 2.7 A).  Knockdown of HYOU1 decreased 
STAT3 phosphorylation mediated by vIL-6, wild type hIL-6, and hIL-6-KDEL (Figure 
2.7 B). This suggests that HYOU1 not only impacts vIL-6 signaling events, but may 
also influence signaling by hIL-6. 
 
DISCUSSION 
KSHV expresses several homologs of human cytokines and chemokines, 
including vIL-6 and multiple viral CC chemokines (vCCLs, previously called vMIPs) 
(195). vIL-6 shares considerable structural and functional homology to hIL-6 and is 
detectable in all KSHV-associated malignancies (64, 194, 197). Patients with these 
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malignancies also have elevated hIL-6 levels (60), and vIL-6 signaling likely 
promotes the proinflammatory signaling of hIL-6 to exacerbate disease. Inhibition of 
hIL-6 signaling to treat KSHV-associated lymphomas has been successful (310), so 
it is plausible that targeting vIL-6 signaling may also be a viable treatment for KSHV-
associated malignancies.  
Many previous reports on vIL-6 used exogenously applied vIL-6 (61, 62, 198-
200). Although this has given valuable insight into the role of this viral cytokine, 
recent publications suggest that vIL-6 is primarily retained within the host cell in the 
ER (206, 207). Evidence that supports this intracellular retention include the fact that 
vIL-6 is secreted at a much slower rate than hIL-6, has glycosylation patterns distinct 
from those seen on secreted cytokines, and is capable of binding intracellular gp130 
to induce signaling (206, 208).  
We utilized affinity purification and mass spectrometry to identify cellular vIL-6 
binding partners. HYOU1 stood out as a potential hit because it had the same 
number of unique peptides as were seen for gp130. HYOU1 is an ER chaperone 
that facilitates protein processing, is involved in the ER stress response, and 
protects cells from hypoxia-induced cell death (295, 296, 301). KSHV-associated 
malignancies often persist in hypoxic environments, such as KS lesions on the lower 
extremities and PEL in oxygen-deprived pleural cavities. Hypoxia is able to induce 
lytic replication due to hypoxia response elements present in the promoter region of 
multiple lytic genes (300). Hypoxic conditions in KSHV-infected cells or tumors may 
create a favorable environment for high HYOU1 expression and function, making 
HYOU1 a relevant protein to investigate in KSHV pathogenesis.  
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Based on HYOU1’s role as a chaperone protein for other secreted factors 
(302), we tested if it modulates the level of vIL-6 in the cell. We found that 
knockdown of HYOU1 reduces endogenous vIL-6 protein levels in latent and lytic 
PEL cells as well as in HEK293 cells when HYOU1 is knocked down prior to 
transfection with a vIL-6 expression construct. Interestingly, in cells that exogenously 
express vIL-6 before knockdown of HYOU1, the effect of HYOU1 on vIL-6 
expression is not significant. Based on HYOU1’s role as a known processing factor 
for VEGF (302), we speculate that HYOU1 may be involved in the processing and/or 
stability, as well as the biological function, of vIL-6.   
Our data also show that HYOU1 enhances vIL-6-mediated STAT3 
phosphorylation, and it is known that vIL-6 can initiate STAT signaling through ER-
associated gp130 (207). We hypothesized that HYOU1’s interaction with vIL-6 could 
place vIL-6 in closer proximity to gp130 as a mechanism to promote signaling. To 
test this, we performed an immunoprecipitation, and found that HYOU1 expression 
does appear to increase the ability of vIL-6 to bind gp130. In addition to increasing 
intracellular vIL-6 levels, promoting the vIL-6-gp130 interaction may be yet another 
way that HYOU1 is able to positively influence vIL-6 function. 
KS lesions are of endothelial cell origin, and exist in a highly inflammatory and 
vascularized environment (29, 32). vIL-6 expression is detectable in the serum of a 
proportion of KS patients (194), and vIL-6 has been shown to influence important 
biological functions of endothelial cells such as differentiation, proliferation, and 
angiogenesis (211, 311). Our data further show that vIL-6 is able to induce the 
migration of endothelial cells in a HYOU1-dependent manner. For this assay, we 
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used serum starved cells to minimize the possibility that proliferating cells could be 
filling the gap as opposed to migrating cells, since vIL-6 has previously been shown 
to increase cell proliferation (61, 198, 207, 211). HYOU1 has a known role in 
facilitating processing of secreted factors including VEGF (302). We therefore 
hypothesized that HYOU1 could modulate chemokines involved in vIL-6-mediated 
cell migration. CCL2 is associated with increased migration of tumor cells and 
immune cells (303, 304). We found that vIL-6 can induce CCL2 expression and that 
knockdown of HYOU1 substantially reduced this vIL-6-mediated increase in CCL2, 
but not quite to the level of CCL2 in cells expressing an empty vector. This suggests 
that HYOU1 may partly influence vIL-6-mediated migration by modulating CCL2 
expression, but that other chemokines or factors are likely involved. Overall, our data 
suggest that HYOU1 may have multiple mechanisms by which it promotes vIL-6 
function in signaling, endothelial cell migration, and endothelial cell survival in 
serum-starved conditions.  
Since vIL-6 is a homolog of hIL-6, we tested if HYOU1 can also bind the 
human cytokine. Because hIL-6 is rapidly secreted, it is present at levels that are 
undetectable by Western blotting in cell lysates. Therefore, we speculated that it 
would be difficult to demonstrate an interaction between wild type hIL-6 and HYOU1, 
since such an interaction would likely be too transient to detect. We circumvented 
this issue by using a hIL-6 construct with an ER-targeting KDEL motif that increases 
the intracellular retention of hIL-6. We detected an interaction between HYOU1 and 
hIL-6-KDEL, although we could not detect an interaction between wild type hIL-6 
and HYOU1. However, we found that STAT3 signaling mediated by wild type hIL-6 
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was diminished when HYOU1 was depleted from cells. Since HYOU1 can impact 
wild type hIL-6 signaling, we speculate that HYOU1 might transiently interact with 
hIL-6 when the cytokine is transiting through the ER, despite being unable to see an 
interaction between HYOU1 and wild type hIL-6 by immunoprecipitation. 
Alternatively, HYOU1 might have an effect on other components of the hIL-6 
signaling pathway to impact signaling. Overall, our data suggest that HYOU1 may 
play a role in both vIL-6 and hIL-6 signaling function.  
During lytic reactivation of KSHV, vIL-6 is highly expressed and some is 
secreted from infected cells which is likely why patients with MCD and other KSHV-
associated malignancies have detectable vIL-6 in their serum (55, 64). Conversely, 
during latency, vIL-6 is expressed at very low levels that are mainly retained within 
the cell. Importantly, it has been demonstrated that this low level of latent expression 
is functional (207). Inhibition of proinflammatory hIL-6 signaling with an anti-IL-6 
receptor antibody has been moderately successful for the treatment of MCD (310); 
however, inhibiting vIL-6 signaling in a similar fashion may be challenging since 
much of vIL-6 signaling occurs inside the cell beyond reach of an IL-6R-targeting 
antibody. The identification of HYOU1 as a cellular binding partner that is required 
for facilitating multiple facets of vIL-6 function and hIL-6 activity presents an 
alternative druggable target for inhibiting IL-6 function to treat KSHV-associated 
malignancies.  
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CHAPTER 3: KSHV VIRAL INTERLEUKIN 6 MODULATES ENDOTHELIAL CELL 
MOVEMENT BY UPREGULATING CELLULAR GENES INVOLVED IN 
MIGRATION4 
 
OVERVIEW 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of 
Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s 
disease. KSHV utilizes a variety of mechanisms to evade host immune responses, 
promote cellular transformation and growth, and persist for the lifetime of the host. A 
viral homolog of interleukin 6 called viral interleukin 6 (vIL-6) is expressed by KSHV 
and KSHV-associated cancers. Unlike host interleukin 6, vIL-6 is retained within the 
endoplasmic reticulum (ER) where it can initiate functional signaling through part of 
the interleukin 6 receptor complex. We sought to determine how intracellular vIL-6 
modulates the host cell environment by analyzing vIL-6’s impact on the endothelial 
cell transcriptome. vIL-6 significantly altered the expression of many cellular genes 
associated with cell migration. In particular, vIL-6 upregulated the host factor 
carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1) at the 
protein and message level. CEACAM1 has been implicated in tumor invasion and 
                                                          
4 Louise Giffin, John A. West, and Blossom Damania (Manuscript submitted.) BD and 
LG designed experiments. All experiments performed by LG with assistance from 
JAW for viral preparations and infections. Manuscript was written by LG and edited 
by BD. Grants to BD provided funding for all experiments. 
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metastasis and promotes migration and vascular remodeling in endothelial cells. We 
report that vIL-6 upregulates CEACAM1 by a STAT3-dependent mechanism, and 
that CEACAM1 promotes vIL-6-mediated migration. Furthermore, latent and de novo 
KSHV infection of endothelial cells also induces CEACAM1 expression. Collectively, 
our data suggest that vIL-6 modulates cell migration by upregulating expression of 
cellular factors including CEACAM1. 
 
INTRODUCTION 
Kaposi’s sarcoma associated herpesvirus (KSHV, HHV8) is the eighth human 
herpesvirus identified and is the etiological agent of Kaposi’s sarcoma (KS), primary 
effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) (3, 4, 6). 
KSHV-associated malignancies typically present in immunosuppressed patients 
such as HIV-positive individuals, and because of the high AIDS incidence in sub-
Saharan Africa, KS has become the most common cancer amongst African men (17, 
20). KSHV is a gammaherpesvirus that has a double stranded DNA genome and 
enveloped virion (40) and is able to transition between a latent phase and an actively 
replicating lytic phase. The virus expresses over eighty open reading frames 
(ORFs), many of which inhibit various host immune defenses or promote growth and 
transformation of host cells. These strategies allow KSHV to persist for the lifetime of 
the host and induce pathogenesis in immunocompromised individuals.  
 The KSHV protein expressed by ORF K2 is known as viral interleukin 6 (vIL-
6) because of its high sequence and structural similarity to the human cytokine 
interleukin 6 (hIL-6) (195-197). vIL-6 is expressed at low, but functional, levels during 
viral latency and becomes highly upregulated during lytic induction (143, 144, 207). 
73 
Importantly, vIL-6 can be detected in either serum or tissue of patients with KSHV-
associated malignancies, and in MCD, higher vIL-6 levels correlate with poor 
prognosis (55, 64, 194). vIL-6 expression is transforming in NIH-3T3 cells (61), and 
a transgenic mouse line expressing vIL-6 from an MHC class I promoter developed 
a MCD-like disease in a manner dependent on mouse IL-6 (312). vIL-6 drives 
expression of hIL-6 and VEGF (61, 200), and promotes angiogenesis, migration, 
survival, and activation of hIL-6-dependent signaling cascades such as the 
JAK/STAT, MAPK, and PI3K pathways (62, 198, 199, 211, 313). 
 Despite their structural similarities, vIL-6 differs from hIL-6 in that vIL-6 is 
secreted from the cell more slowly and accumulates in the endoplasmic reticulum 
(ER) where it can signal intracellularly through the gp130 subunit of the IL-6 receptor 
(142, 206). To better understand how vIL-6 interacts with host proteins to function 
inside the cell, we previously identified a host protein called hypoxia upregulated 
protein 1 (HYOU1) that plays a critical role in vIL-6-mediated signaling, survival, and 
migration (313). Two other host proteins, VKORC1v2 and calnexin, have also been 
identified as vIL-6-interacting partners and these cellular proteins appear to play a 
role in vIL-6-mediated cell survival and vIL-6 folding and intracellular retention, 
respectively (142, 292, 294).  
We wanted to investigate how intracellular expression of vIL-6 impacts the 
global transcriptional profile of endothelial cells since these cells  can be infected 
with KSHV in vivo and are the cells that drive the development of  KS lesions (31, 
32). To explore the impact of intracellular vIL-6 on gene expression, we performed 
microarray analysis on endothelial cells stably expressing vIL-6. We identified some 
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genes known to be upregulated by vIL-6 (61, 200, 313), and also found a number of 
genes that were previously not known to be upregulated by vIL-6.  In particular,  vIL-
6 increased expression of a number of genes significantly associated with cell 
invasion and endothelial cell movement and chemotaxis, including a gene called 
carcinoembryonic antigen-related adhesion molecule 1 (CEACAM1).  
CEACAM1 (also known as CD66a and biliary glycoprotein) is a 
transmembrane adhesion molecule that is expressed in a number of different cell 
types, including endothelial, epithelial, and hematopoietic cells (314). Although some 
earlier studies reported that CEACAM1 expression decreases in colorectal cancer 
(315), more recent clinical studies and profiling in a wide variety of human tumors, 
including colon (316), melanoma (317-319), lung (320), pancreas (321), bladder 
(322, 323), and thyroid (324) cancers found that high levels of CEACAM1 are 
expressed on tumor cells and that CEACAM1 expression directly correlates with 
poor prognosis and tumor metastasis. CEACAM1 may also play a role in dampening 
the immune response to cancer, which may contribute to cancer progression (325). 
In addition, CEACAM1 has consistently been shown to augment angiogenesis, 
increase migration of endothelial cells, and induce vascular remodeling (326-330). 
Interestingly, human cytomegalovirus (hCMV) encodes a viral homolog of 
CEACAM1 which has also been shown to be important in promoting angiogenesis 
(331). 
We found that expression of vIL-6 and de novo and latent KSHV infection 
upregulate CEACAM1 transcript and protein levels in endothelial cells. We 
determined that CEACAM1 expression is likely driven by vIL-6-mediated STAT3 
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signaling. Finally, we found that knockdown of CEACAM1 abrogated vIL-6-mediated 
migration of endothelial cells, indicating that CEACAM1 may play a critical role in 
promoting invasion and pathogenesis of KSHV-infected endothelial cells.  
 
METHODS 
Cell Culture, Generation of Stable Cell Lines, and KSHV Infection 
hTERT-immortalized human umbilical vein endothelial cells (hTERT-HUVEC) 
and primary HUVEC were grown in EBM-2 (Lonza) with the EBM-2 bullet 
supplement (Lonza) as described (178). TREx BCBL1 and TREx BCBL1-RTA PEL 
cells (305) were kindly provided by Dr. Jae Jung’s lab and were grown in RPMI 1640 
medium (Corning) containing Tet System Approved FBS (Clontech) and 20 μM 
hygromycin B (Roche). All media were supplemented with 10% heat inactivated fetal 
bovine serum (FBS), 1% penicillin-streptomycin (PS), and 1% L-glutamine. hTERT-
HUVEC stably expressing empty vector or FLAG-tagged vIL-6 were generated by 
lentiviral transduction as described previously (313). KSHV was produced by 
reactivating KSHV-Vero cells with 2 mM sodium butyrate (Sigma) and ORF50-
expressing baculovirus. Supernatants were clarified and filtered and purified KSHV 
was isolated by ultracentrifugation on a sucrose cushion, as described previously 
(223). Stable, latently infected KSHV-HUVEC were made by infecting hTERT-
HUVEC with recombinant KSHV as described previously (332).  
Plasmids, Lentiviral vectors, and siRNAs  
The pcDNA3.1-vIL-6-His clone was a kind gift from Yuan Change and Patrick 
Moore. A C-terminal FLAG tag was added to vIL-6 and cloned into the pcDNA3.1 
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eukaryotic expression vector (Life Technologies). The non-targeting control (NTC) 
siRNA duplex (D001810-01) was purchased from Dharmacon. CEACAM1-targeting 
Stealth siRNA duplexes were purchased from Life Technologies (HSS101005). 
FLAG-tagged vIL-6 was cloned into the lentiviral vector pSuper-CMV Puro (Life 
Technologies) and all lentiviruses were produced using the ViraPower Lentiviral 
Expression System (Life Technologies) as per the manufacturer’s instructions.  
Microarray and Ingenuity Pathway Analysis 
RNA was harvested from hTERT-HUVEC stably expressing empty vector or 
vIL-6-FLAG using TRIzol, and checked for quality with an Agilent Bioanalyzer. One 
μg of RNA was submitted to Mogene for use with the 4x44K Human Microarray 
(Agilent). Samples were run in duplicate with Cy3 and Cy5 dyes switched for each 
sample to correct for any fluorescence dye bias. Preliminary analysis was completed 
by Mogene and fold changes for each gene were reported. Gene names and 
corresponding fold changes were input into Ingenuity Pathway Analysis and 
analyzed using a fold change cutoff of 2.0 with “experimentally observed” confidence 
and a stringent filter for mammalian species specificity. Top diseases and biological 
functions were analyzed and gene lists and p-values for cell invasion and endothelial 
cell movement and chemotaxis were exported. 
Reagents and Antibodies  
The S3I-201 STAT3 inhibitor (Selleck Chem) was dissolved in DMSO (Sigma) 
and used at a concentration of 60-75 μM for 48-72 hours. Recombinant hIL-6 
(Peprotech) was resuspended in distilled deionized water and used at a 
concentration of 100 or 250 ng/mL. Primary antibodies used were ECS (FLAG - 
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Bethyl), vIL-6 (Advanced Biotechnologies), Tubulin, CEACAM1, phospho-STAT3 
Tyr705, and Total STAT3 (all from Cell Signaling unless otherwise stated). 
Secondary anti-rabbit and anti-mouse antibodies were purchased from Cell 
Signaling.  
Western Blotting  
Cells were washed in cold PBS and harvested in NP-40 lysis buffer (0.1% 
NP-40, 150 mM NaCl, 50 mM Tris HCl pH 8.0, 30 mM β-glycerophosphate, 50 mM 
NaF, 1 mM Na3VO4, 1 Roche protease inhibitor tablet per 50 mL) for 10-30 minutes 
on ice. Lysates were frozen and thawed and clarified by centrifugation at 16,000 x g 
for 10 minutes. Protein content was determined by Bradford assay (Bio-Rad) using a 
CLARIOstar Optima plate reader (BMG Labtech). Equal amounts of protein were 
resolved on 8% SDS-PAGE gels and transferred to nitrocellulose membranes. 
Membranes were blocked with 5% non-fat dry milk in 1x TBS/0.1% Tween followed 
by overnight incubation with primary antibody at 4oC. HRP-conjugated secondary 
antibodies were incubated for 1 hour at room temperature. Blots were developed 
with PicoWest chemiluminescent reagent (Thermo).  
RNA Isolation and Real Time qPCR 
Cells were washed in cold PBS and resuspended in TRIzol 
(LifeTechnologies) and RNA was harvested as per the manufacturer’s instructions. 
To generate cDNA, 1 μg of RNA was treated with amplification grade DNAse I 
(Invitrogen) followed by reverse transcription with Superscript III reverse 
transcriptase (Invitrogen) and oligoDT primers (Invitrogen). Quantitative real-time 
PCR (qPCR) was performed with an Advanced Biotechnologies 7300 instrument 
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using cDNA as a template in a SYBR green PCR master mix (Bio-Rad). Primers for 
Total CEACAM1 (Forward: 5’AATGTTGCAGAGGGGAAGGA 3’; Reverse: 5’ 
TCTGGGTGACGTTCTGGATC 3’) , CEACAM1-Long (Forward: 
5’CCCACCTAACAAGATGAATGAA 3’; Reverse: 5’ TTTCTGTGGCTGTTAGGGATG 
3’),  vIL-6 (Forward: 5’ CGGTTCACTGCTGGTATCTG 3’; Reverse: 5’ 
CAGTATCGTTGATGGCTGGT 3’), and ORF57 (Forward: 5’ 
TGGACATTATGAAGGGCATCCTA 3’; Reverse: 5’ CGGGTTCGGACAATTGCT 3’) 
were used with GAPDH as an endogenous control. PCR reactions were run in 
triplicate.   
KSHV Infection and Reactivation 
De novo infections were performed by infecting primary HUVEC (Clonetics) 
with purified KSHV by spinoculation in serum-free media in the presence of 8 μM 
polybrene (Sigma) at 2500 rpm for 1.5 hours at 30oC in a table top centrifuge as 
previously described (223). GFP was visualized on a Nikon Ti Eclipse fluorescent 
microscope to confirm infection and samples were harvested 30-72 hours post 
infection. TREx-BCBL1 were reactivated by supplementing media with 1 μg/mL 
doxycycline for 24-30 hours. 
Migration Assay 
hTERT-HUVEC expressing empty vector or FLAG-tagged vIL-6 were seeded 
at 0.9 x 105 cells per well of a 6 well dish coated with collagen IV (Corning Biocoat) 
since collagen IV is a known adhesion substrate of CEACAM1 (324). The following 
day cells were transfected with 60 nM of an NTC or CEACAM1-targeting siRNA 
using Lipofectamine RNAimax as per the manufacturer’s instructions. Media were 
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replaced 24 hours post-transfection and at 40 hours post-transfection cells were 
serum starved for 8 hours. Monolayers were then scratched with a P200 pipette tip 
and brightfield images were obtained at 0, 15, and 24 hours post-scratch at 40x 
magnification with a Nikon Eclipse Ti inverted microscope. Following the assay, cells 
were harvested in lysis buffer and analyzed by SDS-PAGE and Western blotting to 
test CEACAM1 knockdown efficiency. Scratch closure was quantified with ImageJ 
software (NIH) (333). 
 
RESULTS 
Intracellular vIL-6 Induces Expression of Genes Involved in Cell Migration 
 To investigate the effect of intracellular vIL-6 expression on the transcriptome 
of human endothelial cells, an Agilent 4x44K human microarray was performed in 
duplicate using RNA harvested from hTERT-HUVEC expressing empty vector (EV) 
or FLAG-tagged vIL-6 (vIL-6F). Ingenuity Pathway Analysis (IPA) software was 
utilized to identify major disease pathways affected by vIL-6 expression. IPA found 
that vIL-6 significantly impacted pathways associated with cancer, cellular 
movement, and cell-cell signaling and interaction (Figure 3.1 A). We further 
investigated the impact of vIL-6 on genes associated with cellular movement since 
we previously reported that vIL-6 can promote the migration of endothelial cells 
(313). We found that there were a significant number of genes associated with 
endothelial cell movement, endothelial cell chemotaxis, and cell invasion that were 
altered by vIL-6 expression (Figure 3.1 B). Furthermore, based on how vIL-6 
influenced the expression of these migration-associated genes, IPA predicted that 
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vIL-6 should induce cellular migration, thus confirming our previous findings (313). In 
addition to the identification of many previously unidentified vIL-6 target genes, we 
also found  some genes known to be upregulated by vIL-6, including the host 
chemokine CCL2 (313), VEGF (61), and hIL-6 (200) (Figure 3.1 C). 
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Figure 3.1: vIL-6 modulates expression of host genes associated with cell movement. 
(A) RNA was harvested from HUVEC expressing empty vector or FLAG-tagged vIL-6 and 
used in an Agilent 4x44K human microarray. Gene fold changes were imported into 
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Ingenuity Pathway Analysis (IPA) and top vIL-6 associated diseases and biological functions 
were analyzed. (B) Top modulated genes from selected cell movement-associated sub-
pathways from IPA. Fold change values represent vIL-6-expressing cells as compared to 
empty vector cells, and predicted cell movement phenotype represents IPA’s prediction of 
how cells will respond based on the expression pattern of that particular cellular gene and 
the IPA literature database. p values calculated by IPA represent how significantly vIL-6 
expression impacts genes associated with that particular sub-pathway. (C) Microarray data 
for genes known to be upregulated by vIL-6: VEGF, CCL2, and human IL-6. 
 
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a 
gene associated with cellular movement and invasion that was almost 12-fold 
upregulated in our vIL-6-expressing hTERT-HUVEC (Figure 3.1 B). We confirmed 
that expression of FLAG-tagged vIL-6 in hTERT-HUVEC significantly upregulates 
CEACAM1 mRNA message as compared to empty vector by qPCR (Figure 3.2 A). 
Lysates from hTERT-HUVEC stably expressing empty vector or FLAG-tagged vIL-6 
indicate that vIL-6 expression also upregulates CEACAM1 protein in endothelial 
cells (Figure 3.2 B). CEACAM1 has numerous isoforms that arise from alternative 
splicing of the transcript (Figure 3.2 C) (314). These isoforms exist in three general 
categories: secreted CEACAM1 that lacks a transmembrane domain, long isoforms 
of CEACAM1 (CEACAM1-L) that contains an intracellular immunoreceptor tyrosine 
inhibitory motif (ITIM) that can modulate downstream signaling, and short isoforms 
(CEACAM1-S) that lacks this intracellular signaling domain on the cytoplasmic tail. 
The ratios of each isoform can also differ between cell types, and dictate the 
outcome of CEACAM1 expression (334, 335). Higher amounts of CEACAM1-L in 
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cancer correlate with metastatic spread and shorter patient survival (336, 337).  We 
speculated that the two species of CEACAM1 visible by Western blot represent the 
long and short isoforms of this protein, but to confirm that the long isoforms are 
expressed we performed additional qPCR experiments with primers specific to the 
nucleotides encoding the ITIM region of CECAM1-L. We found that vIL-6 induces 
not only total CEACAM1 message, but also CEACAM1-L (Figure 3.2 D).  
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Figure 3.2: vIL-6 upregulates long isoforms of CEACAM1 in endothelial cells. (A) 
cDNA was generated from HUVEC stably expressing empty vector or FLAG-tagged vIL-6 
and used for qPCR analysis of total CEACAM1 message. (B) Lysates were harvested from 
HUVEC stably expressing empty vector or FLAG-tagged vIL-6. SDS-PAGE and Western 
blotting was performed for the indicated proteins. (C) CEACAM1 exists in a number of 
transmembrane and secreted isoforms that differ in the number and type of extracellular Ig 
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domains, and presence or absence of a transmembrane domain, a long cytoplasmic tail, 
and an Alu repeat. (D) cDNA was generated from HUVEC stably expressing empty vector or 
FLAG-tagged vIL-6 and used for qPCR analysis of total CEACAM1 message and 
CEACAM1-L message. 
 
vIL-6 Upregulates CEACAM1 Through Activation of STAT3 
 vIL-6 is a potent activator of STAT3 (142, 199, 205, 313), so we sought to 
determine if vIL-6-mediated STAT3 signaling is the mechanism by which vIL-6 
upregulates CEACAM1 message and protein. S3I-231 is a small molecule that 
inhibits the ability of STAT3 to dimerize and become activated (338). We treated 
hTERT-HUVEC stably expressing empty vector or FLAG-tagged vIL-6 with 60 uM 
S3I-231 or vehicle control (DMSO) for 48 hours. RNA was harvested and qPCR was 
performed. In vehicle-treated cells, CEACAM1 levels were much higher in vIL-6 cells 
as compared to empty vector cells; however, treatment with S3I-201 greatly reduced 
CEACAM1 transcript levels in vIL-6 cells (Figure 3.3 A). Furthermore, treatment of 
cells with S3I-201 for 72 hours significantly reduced CEACAM1 protein in vIL-6 cells 
as compared to the vehicle control (Figure 3.3 B).  Western blots confirmed that 
Tyr705 phosphorylation of STAT3 was increased by expression of vIL-6, and that 
treatment with S3I-201 reduced STAT3 phosphorylation, as expected (Figure 3.3 B). 
This data suggests that STAT3 signaling may play a role in vIL-6-mediated 
upregulation of CEACAM1. 
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Figure 3.3: vIL-6, but not hIL-6, upregulates CEACAM1 in a STAT3-dependent manner. 
(A) cDNA was generated from HUVEC stably expressing empty vector or FLAG-tagged vIL-
6 that were treated with DMSO or 60 μM S3I-201 for 48 hours in media containing 2% 
serum. qPCR was performed to assess levels of total CEACAM1 message. (B) Lysates 
were harvested from HUVEC stably expressing empty vector or FLAG-tagged vIL-6 that 
were treated with DMSO or 75 μM S3I-201 for 72 hours in media containing 10% serum. 
SDS-PAGE and Western blotting for the indicated proteins was performed. (C) HUVEC 
stably expressing empty vector or FLAG-tagged vIL-6 were treated with exogenous hIL-6 for 
48 hours. cDNA was generated and analyzed for total CEACAM1 message by qPCR. (D) 
HUVEC stably expressing empty vector or FLAG-tagged vIL-6 were treated with exogenous 
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hIL-6 for 48 hours. Lysates were harvested and subjected to SDS-PAGE and Western 
blotting for the indicated proteins. 
 
Human Interleukin-6 Does Not Influence CEACAM1 Expression 
 Since vIL-6 and human interleukin-6 (hIL-6) share homology, we wanted to 
determine if hIL-6 alone, or in combination with vIL-6, can drive CEACAM1 
expression. We treated hTERT-HUVEC stably expressing empty vector or FLAG-
tagged vIL-6 with 0, 100, or 250 ng/mL of recombinant hIL-6 for 48 hours total in 2% 
serum, with fresh media and fresh hIL-6 supplemented at 24 hours. RNA and lysates 
were harvested from these cells and Western blotting and qPCR was performed. 
Phosphorylation of STAT3 Tyr705 was induced in empty vector cells upon hIL-6 
treatment, although not nearly to the high levels seen in vIL-6-expressing cells 
(Figure 3.3 D). Interestingly, exogenous hIL-6 did not increase CEACAM1 
expression either in the empty vector cells or the vIL-6-expressing cells at either the 
protein (Figure 3.3 D) or transcript (Figure 3.3 C) level. We also treated cells with 
100 ng/mL hIL-6 treatment for 72 hours, and similar trends were seen (data not 
shown). This suggests that intracellular vIL-6 is unique in its ability to drive 
CEACAM1 expression in endothelial cells, despite its similarities to hIL-6.  
 
CEACAM1 Is Required for Migration of vIL-6 Expressing Endothelial Cells 
Based on CEACAM1’s proposed role in invasion and metastasis of a number 
of cancers (319, 323, 324), we wanted to determine if it plays a role in the biological 
function of vIL-6. We utilized hTERT-HUVEC stably expressing empty vector or 
FLAG-tagged vIL-6 that were plated onto dishes coated with collagen IV as 
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previously described (324). We transfected cells with a non-targeting or CEACAM1-
targeting siRNA, and 40 hours post-transfection, cells were serum starved for 8 
hours. Monolayers were scratched with a P200 pipette tip and triplicate images of 
each scratch were captured at 0, 15, and 24 hours post-scratch (Figure 3.5 A). 
ImageJ software was utilized to trace and quantify the remaining area of each 
scratch at 15 and 24 hours post-scratch as compared to the area of each scratch at 
0 hours (Figure 3.5 B). vIL-6 cells expressing CEACAM1 rapidly migrated and 
closed the scratch as compared to empty vector cells; however, knockdown of 
CEACAM1 reduced the ability of vIL-6-expressing cells to close the gap as fast. 
Following completion of the assay, lysates were harvested for SDS-PAGE and 
Western blotting to confirm CEACAM1 knockdown (Figure 3.5 C). This suggests that 
CEACAM1 plays a role in vIL-6-mediated migration of endothelial cells.   
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Figure 3.4: CEACAM1 facilitates vIL-6-mediated endothelial cell migration. (A) HUVEC 
stably expressing empty vector or FLAG-tagged vIL-6 were plated on collagen IV coated 
plates. Cells were transfected with 60 nM non-targeting (NTC) or CEACAM1-targeting 
siRNA (CEA-siRNA) for 40 hours. Cells were serum starved for 8 hours and the monolayers 
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were scratched with a P200 pipette tip. Brightfield images were obtained at 40x 
magnification with a Nikon Eclipse Ti inverted microscope at 0, 15, and 24 hours post-
scratch. Three images were taken of each individual scratch, with representative images 
shown. (B) Scratch assays were quantified using ImageJ software. The starting scratch area 
was determined and set at a value of 1, and at subsequent time points, scratch areas were 
divided by the original scratch area to normalize for variation in the original size of each 
scratch. Three images and measurements were taken for each time point for each scratch 
and averaged, and the graph and error bars were determined by the average of two 
independent experiments. (C) After the 24 hour scratch assay time point, cell lysates were 
harvested and subjected to SDS-PAGE and Western blot for the indicated proteins to 
confirm CEACAM1 siRNA knockdown.  
 
CEACAM1 is Upregulated by KSHV Infection in Multiple Cell Types 
We next wanted to determine if CEACAM1 is upregulated following KSHV 
infection. vIL-6 is expressed at low but functional levels during latency (207) and is 
highly upregulated during lytic infection or lytic reactivation (143, 144). We first 
investigated if de novo infection of primary HUVEC with a recombinant KSHV virus 
expressing GFP (339) could induce CEACAM1 upregulation. Upon KSHV infection 
in endothelial cells, the virus undergoes several brief rounds of lytic infection before 
establishing latency (340). At 30 hpi, almost 100% of cells receiving KSHV were 
GFP positive whereas the mock control was not (Figure 3.5 A). RNA and lysates 
were harvested and analyzed by qPCR and Western blotting, respectively. Ample 
vIL-6 message was detected in addition to another lytic transcript, ORF57, further 
confirming successful KSHV infection (Figure 3.5 B). CEACAM1 message was 
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upregulated over 6 fold in KSHV-infected cells as compared to mock control (Figure 
3.5 C), and we were also able to detect significant upregulation of CEACAM1protein 
in infected cells by Western blot (Figure 3.5 D).  
 
Figure 3.5: CEACAM1 is upregulated during de novo and latent KSHV infection of 
endothelial cells and during reactivation in PEL. (A) PBS (mock) or 150 μL purified 
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KSHV was added to primary HUVEC in the absence of serum followed by spinoculation. 
The following morning serum was added to 10% and 30 hours post-infection brightfield and 
GFP images at 100x magnification were obtained using a Nikon Eclipse Ti inverted 
microscope. (B) RNA was harvested and cDNA was generated from mock and KSHV-
infected primary HUVEC at 30 hours post infection. qPCR was performed for the lytic 
transcripts vIL-6 and ORF57 and total CEACAM1 (C). (D) Lysates were harvested from 
mock and KSHV-infected primary HUVEC at 30 hours post infection and subjected to SDS-
PAGE and Western blotting for the indicated proteins. (E) RNA was harvested and cDNA 
was generated from uninfected hTERT-HUVEC and latent KSHV-HUVEC. qPCR was 
performed for total CEACAM1. (F) Lysates were harvested from uninfected hTERT-HUVEC 
and latent KSHV-HUVEC and subjected to SDS-PAGE and Western blotting for the 
indicated proteins. (G) TREx-BCBL1 and TREx-BCBL1-RTA were treated with 1μg/mL 
doxycycline for 24 hours. RNA was harvested and cDNA was generated. qPCR was 
performed to analyze levels of total CEACAM1 and CEACAM1-L. (H)  TREx-BCBL1 and 
TREx-BCBL1-RTA were treated with 1μg/mL doxycycline for 24 hours. Lysates were 
harvested and resolved by SDS-PAGE followed by Western blotting for the indicated 
proteins. 
 
We then analyzed CEACAM1 message and protein levels in uninfected 
hTERT-HUVEC or latently infected KSHV-HUVEC that we had previously 
established and described (332). We found that CEACAM1 was also upregulated at 
the message and protein level in the latent KSHV-HUVEC (Figure 3.5 E and F).  
To test another physiologically relevant cell line for the impact of KSHV 
infection on CEACAM1 expression, we used a latently infected PEL cell line, BCBL1. 
TREx BCBL1-RTA stably express a doxycycline inducible RTA expression plasmid, 
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and are reactivated within 24 hours of doxycycline addition as previously described 
(305). The control line, TREx BCBL1, expresses a doxycycline inducible empty 
vector, and maintains a latent infection upon doxycycline addition. These two cell 
lines were treated with 1 μg/mL Doxycycline for 24 hours prior to harvest of RNA and 
lysates. Interestingly, we found that reactivation of these cells caused a large 
increase in a single discrete species of CEACAM1 by Western blotting as compared 
to latent cells (Figure 3.5 H). We performed qPCR on RNA harvested from the TREx 
BCBL1, and noted that total CEACAM1 message was upregulated in reactivated 
cells (Figure 3.5 G). We also quantified the long isoform of CEACAM1 using an 
ITIM-specific primer set and found that the long isoforms of CEACAM1 are not 
dramatically upregulated in lytic cells as compared to latent cells, although total 
CEACAM1 is still highly increased in lytic cells. Collectively, our data suggest that 
CEACAM1 expression is increased during both primary and latent KSHV infection 
and in the context of reactivation in multiple physiologically relevant cell types.  
 
DISCUSSION 
 The human herpesviruses are unique from most other viral classes because 
they persist for the lifetime of the host. To accomplish this, herpesviruses must 
intricately modulate their surroundings to create a favorable environment for 
propagation. The KSHV genome encodes an arsenal of proteins and small RNAs 
that help the virus persist via a number of mechanisms including direct and indirect 
evasion of the host immune system, modulation of host cell signaling, and mimicry of 
host chemokines and cytokines. For example, KSHV encodes several viral 
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homologs of cellular interferon regulatory factors (IRFs) that abrogate host IRF 
signaling to diminish an interferon response to the virus (225). In addition to the viral 
IRFs, KSHV encodes other homologs to cellular proteins including vIL-6, which is a 
viral cytokine that has functional and structural similarity to hIL-6 (195, 197).  
vIL-6 and elevated hIL-6 are detectable in all KSHV-associated malignancies 
(60, 64, 194) and these two cytokines likely work in a synergistic manner to create a 
pro-inflammatory environment that promotes disease. Despite their similarities, hIL-6 
and vIL-6 have differential requirements for signaling through the IL-6-receptor (IL-
6R): the gp80 and gp130 IL-6R subunits are essential for hIL-6 signaling, but vIL-6 
can signal through gp130 in the absence of gp80 (201, 203). Since gp80 is 
predominantly on the cell membrane, this limits hIL-6 to extracellular signaling, 
whereas vIL-6 is able to signal intracellularly through ER-embedded gp130 (207). 
Furthermore, hIL-6 is rapidly secreted from cells, but vIL-6 is primarily retained within 
the ER (206). Based on its unique intracellular localization and intracellular signaling 
capabilities, we were curious as to how vIL-6 might use or modulate the intracellular 
host environment to promote its function.  
We previously reported that vIL-6 interacts with a cellular ER protein called 
HYOU1, and that HYOU1 was important for vIL-6-induced JAK/STAT3 signaling, 
migration, and serum-starved survival in endothelial cells (313). Interestingly, vIL-6-
mediated endothelial cell migration was dependent in part on HYOU1-facilitated 
expression of the host chemokine CCL2. We speculated that vIL-6 may influence 
expression of a number of additional host genes to promote vIL-6 mediated 
biological processes such as endothelial cell chemotaxis and angiogenesis. A 
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previous study analyzed the impact of vIL-6 on the expression of several hundred 
cellular genes in a hepatoma cell line; however, this group used exogenously 
applied bacterially-derived vIL-6 and only a limited number of transcripts were 
analyzed (62). vIL-6 requires glycosylation derived from mammalian cell machinery 
for it to be fully functional (341), and it is now known that vIL-6 functions 
intracellularly (142, 206), so exogenous application of vIL-6 is less physiologically 
relevant. The impact of intracellular vIL-6 expression specifically on the endothelial 
cell transcriptome is a previously unexplored area, and endothelial cells are 
extremely relevant to KSHV infection since these cells are infected in vivo and can 
give rise to KS (31, 32).  
We performed a human microarray on hTERT-HUVEC stably expressing an 
empty vector or FLAG-tagged vIL-6. Our data confirmed previous reports that vIL-6 
upregulates the host genes CCL2, VEGF, and hIL-6 (Figure 3.1 C). We also found 
that vIL-6 expression altered genes associated with endothelial cell movement and 
chemotaxis and cell invasion (Figure 3.1 B). One gene, CEACAM1, was highly 
upregulated by vIL-6 expression. CEACAM1 is an adhesion protein that is implicated 
in a number of human cancers and can promote angiogenesis, migration, and 
vascular remodeling in endothelial cells (326-330). Because KS is a highly 
angiogenic tumor, we wanted to further investigate the induction of CEACAM1 
expression by vIL-6.    
  We sought to determine the mechanism by which vIL-6 mediates the increase 
in CEACAM1 transcription. It has been previously shown that knockout of STAT3 
can reduce CEACAM1 expression in APCmin mice (342), and vIL-6 is a known 
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inducer of STAT3 signaling (142, 199, 205, 343).  Inhibition of STAT3 activity with 
S3I-201 reduced the level of both CEACAM1 message and protein in vIL-6-
expressing endothelial cells. Interestingly, hIL-6 did not upregulate CEACAM1 
despite its known ability to activate STAT3. There are several possibilities that could 
explain this: first, exogenously applied hIL-6 activates STAT3 to a lesser degree 
than intracellularly-expressed vIL-6, so it is possible that hIL-6-induced STAT3 
activity is not adequate to impact CEACAM1 expression. Another possibility is that 
vIL-6 is inducing a unique intracellular pathway capable of upregulating CEACAM1. 
hIL-6 can only signal from gp80-containing IL-6R complexes found exclusively on 
the plasma membrane, so it is possible that vIL-6 can activate an intracellular 
mechanism from the ER that hIL-6 does not have access to.  Pathways uniquely 
activated by intracellular vIL-6 as compared to extracellular hIL-6 could be an 
interesting avenue of investigation for KSHV treatment, since this would allow for 
specific targeting of virally-activated pathways.   
Since CEACAM1 can promote the movement and invasive capability of 
endothelial cells (323, 327), we investigated whether vIL-6-mediated upregulation of 
CEACAM1 plays a role in cell movement. In the presence of CEACAM1, vIL-6-
expressing endothelial cells migrated rapidly, but knockdown of CEACAM1 
abrogated the ability of these cells to migrate. Knockdown of CEACAM1 in empty 
vector HUVEC also reduced migration to a small degree, which is expected since 
CEACAM1 is known to affect cell migration outside the context of vIL-6. These data 
suggest a significant biological function of vIL-6 through its ability to upregulate  
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CEACAM1 expression to induce increased migration of endothelial cells. 
Previous microarray studies using immortalized dermal microvascular 
endothelial cells with a predominantly latent KSHV infection also reported that 
CEACAM1 was one of multiple genes affected by KSHV infection 
(344).Furthermore, CEACAM1 was found to be upregulated in the lungs of mice 
infected with the murine gammaherpesvirus MHV68 (345, 346). In the present study, 
we found that both KSHV latent and de novo infection in endothelial cells 
upregulated CEACAM1 as compared to uninfected cells, and reactivation of PEL 
also resulted in increased CEACAM1 expression. It was recently shown that 
CEACAM1 expression is important for survival of naïve B cells and for proliferation 
of activated B cells, so KSHV’s induction of CEACAM1 expression in PEL may be a 
mechanism by which the virus promotes survival of infected B cells in PEL and/or 
MCD (347). In endothelial cells, however, we speculate that vIL-6’s upregulation of 
the long isoforms of CEACAM1 contributes to the ability of these infected cells to 
promote vascular remodeling, migration, and invasion.  
Collectively, our data have uncovered many previously unidentified cellular 
genes whose expression is changed when vIL-6 is expressed in endothelial cells. 
We have also identified a novel host protein, CEACAM1, induced by KSHV vIL-6, as 
well as in the context of latent and de novo KSHV infection in endothelial cells and 
during reactivation in PEL cells. Based on CEACAM1’s established role in 
angiogenesis, vascular remodeling, cell migration, and cancer metastasis, vIL-6-
induced CEACAM1 may be a very important player in promoting KSHV-associated  
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pathogenesis, particularly for endothelial cell-derived Kaposi’s sarcoma. Our results 
further elucidate the function of intracellular vIL-6 in KSHV biology, and have 
identified CEACAM1 as a migration-associated factor that may be a novel 
therapeutic target for KSHV-associated disease.   
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CHAPTER 4: ALTERATION OF THE HOST CELL KINOME BY LYTIC AND 
LATENT KAPOSI’S SARCOMA ASSOCIATED HERPESVIRUS INFECTION5 
 
OVERVIEW 
 Kinases regulate many sensitive signaling pathways and processes within the 
cell. Cancerous cells often have dyregulated kinase activity, and numerous selective 
kinase inhibitors are on the market or under investigation with the goal of restoring 
normal kinase activity in cancer cells or selectively eliminating these cells. Primary 
effusion lymphoma (PEL) is a B cell neoplasia associated with Kaposi’s sarcoma-
associated herpesvirus (KSHV) infection. PEL cells typically harbor a latent KSHV 
infection, but can undergo lytic reactivation in which a wider array of viral proteins is 
expressed and viral progeny are produced. We utilized a novel kinome profiling 
technique using multiplex inhibitor beads coupled with mass spectrometry (MIB/MS) 
to characterize the activated kinome in PEL cells undergoing latent or lytic infection. 
We identified numerous kinases that were differentially activated during these stages 
of the viral lifecycle. This work has uncovered novel kinases that may be effective 
targets for the treatment of KSHV-associated malignancies    
                                                          
5 Experiments were designed by Blossom Damania and Louise Giffin. LG prepared 
all samples for MIB/MS and Gary Johnson and members of his lab, including 
Deborah Granger, Tim Stumiller, Noah Sciaky, Rachel Reuther, and Trang Pham, 
performed MIB/MS and critical analysis.  Grants to BD provided funding for these 
experiments. 
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INTRODUCTION 
The human genome encodes over 500 protein kinases (collectively called the 
kinome) which regulate the activation of numerous signaling pathways in the cell by 
catalyzing the phosphorylation of cellular proteins and substrates. Upon 
phosphorylation by a kinase, a substrate’s conformation changes, which may then 
alter that substrate’s enzymatic properties, cellular localization, and ability to interact 
with and modulate other proteins and substrates. Abnormal activation or inactivation 
of particular kinases is thought to be one of the major driving forces by which cells 
escape growth regulation and become cancerous (348). Because of this, kinase 
inhibitors have become an intense focus of investigation in drug development, and 
there are currently over 130 selective kinase inhibitors in development as cancer 
chemotherapeutics (349). However, many studies have reported that cancer cells 
have the unique ability to reprogram their kinome to compensate for chemical 
inhibitor treatments or radiation therapy (350-353) which highlights the important 
issue of drug resistance in tumors.  To compete in this war against cancer, it will be 
crucial to understand the baseline activation status of the kinome in various cancers, 
and also to understand what kinase or kinases need to be targeted to effectively and 
permanently inhibit cancer cell growth. Kinome profiling has recently identified 
promising novel kinase targets in triple negative breast cancer and acute 
lymphoblastic leukemia (354, 355).  The application of this technology to other types 
of cancer has huge potential for the development of more efficacious 
chemotherapeutic drugs.   
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KSHV modulates the activation of many kinase-regulated cellular signaling 
pathways. Upon entry into the cell, KSHV infection activates numerous kinases and 
pathways including focal adhesion kinase (FAK), PI3K, Src, MAPK, and NFκB (356-
360). Activation of these pathways allows the viral genome to be transported to the 
nucleus and facilitates viral gene expression (361, 362). KSHV expresses many viral 
signaling proteins during the lytic cycle that can activate various cell signaling 
pathways. For example, the JAK/STAT pathway is activated by vIL-6 (62, 199), the 
PI3K/AKT/mTOR pathway is activated by K1 and vGPCR (171, 189), the NFκB  
pathway is activated by vGPCR and K15 (218, 363), and the MAPK pathway is 
activated by vGPCR, vIL-6, and K15 (198, 218, 364). During latency, KSHV 
expresses a limited repertoire of viral proteins and viral microRNAs that also 
modulate cell signaling pathways. For example, LANA can interact with the cellular 
kinase, GSK3, to facilitate expression of cyclin and myc to drive cell proliferation 
(94), and vCyclin activates cyclin dependent kinase 6 (CDK6) and phosphorylates 
histones to promote entry into S phase (98, 101).  
PEL is an aggressive cancer with a median survival time of only 6 months 
(46). Currently, there is no standard therapy for PEL and patients are typically 
treated with traditional chemotherapy combined with anti-retroviral therapy (ART) if 
patients are HIV positive (365). On a case-by-case basis, patients have been treated 
with preclinical targeted therapeutics to inhibit NFκB, PI3K/AKT/mTOR, JAK/STAT, 
VEGF, and CD30, and there has been limited success with some of these strategies 
(365). Despite these advances, PEL is notoriously resistant to chemotherapy, so 
novel targeted or combination approaches will be essential to treat this KSHV-
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associated lymphoma. There is also an interest in inducing reactivation of latent 
infection because available herpesvirus drugs such as acyclovir are effective during 
lytic infection. A viral kinase expressed only during the lytic cycle phosphorylates 
acyclovir, then cellular kinases can further modify the compound with the addition of 
one or two more phosphate groups to create a nucleoside analog. This analog 
competes with GTP for incorporation into DNA, and preferentially inhibits the viral 
polymerase, thus impeding replication (366). Therefore, one strategy to cure the cell 
of the virus is to induce lytic reactivation while simultaneously treating with acyclovir-
like drugs. This has been done for other herpesvirus infections such as EBV (367).  
An siRNA screen targeting each of the cellular kinases was recently 
completed to identify cellular kinases that could cause reactivation of KSHV from 
latency (368). A cellular kinase called tousled-like kinase 2 (TLK2) was identified and 
found to be critical for maintenance of latent infection (368). Therefore, an objective 
of this work is to build on this study and compare the activated kinome in PEL with 
either a latent or lytic KSHV infection to identify differentially activated signaling 
pathways, some of which may be potential targets for driving infection towards a lytic 
state.  
To profile the kinome during latent and lytic KSHV infection, we utilized a 
novel technique called multiplex inhibitor bead/mass spectrometry (MIB/MS) (350). 
Activated kinases in a sample are selectively isolated by binding to broad spectrum 
kinase inhibitors attached to beads.  Bound kinases can then be eluted from the 
beads and subjected to mass spectrometry to identify individual active kinases that 
are present in the sample (350, 352). We harvested lysates from a KSHV-infected 
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TREx-BCBL1 PEL cell line that has stable expression of doxycycline-inducible 
empty vector or RTA expression vector to maintain or induce the latent or lytic KSHV 
lifecycle, respectively (305). In our comparison between latent and lytic PEL, we 
found numerous differentially activated kinases. The MIBs also isolated the two 
KSHV-expressed protein kinases, indicating that they are bound by the kinase 
inhibitors used in the bead preparation.  
 
METHODS 
Cell Culture 
 TREx BCBL1 and TREx BCBL1-RTA PEL cells (305) were kindly provided by 
Dr. Jae Jung’s lab and were grown in RPMI 1640 medium (Corning) containing 10% 
heat inactivated Tet System Approved FBS (Clontech), 1% penicillin-streptomycin, 
1% L-glutamine, and 20 μM hygromycin B (Roche). TREx BCBL1-RTA were 
reactivated by supplementing media with 1 μg/mL doxycycline for 24hours. 
Sample Harvest and Preparation 
Suspension PEL cells were pelleted and washed three times in cold PBS. 
Pellets were lysed on ice in MIB lysis buffer [50 mM HEPES (pH 7.5), 0.5% Triton X-
100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM sodium fluoride, 2.5 mM 
sodium orthovanadate, 1X protease inhibitor cocktail (Roche), and 1% each of 
phosphatase inhibitor cocktail 2 and 3 (Sigma)]. Cell lysates were sonicated 3×10 
seconds on ice and centrifuged at 16,000×g in microfuge tubes for 10 minutes at 
4°C. The supernatant was syringe-filtered through a 0.2 µm SFCA membrane. 
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Protein concentration was determined by Bradford assay (Biorad) and equal 
amounts of protein, around 2.5 mg, were used for each sample.  
MIB/MS Technique and Analysis 
The filtered lysate was brought to 1 M NaCl and passed through a column of 
multiplexed kinase inhibitor-conjugated beads (MIBs) consisting of Sepharose-
conjugated Purvalanol B, PP58, CTx-0294885, VI16832, and two novel custom-
synthesized pan-kinase inhibitor compounds (352). The MIBs were washed with 5 
mL of high-salt buffer and 5 mL of low-salt buffer [50 mM HEPES (pH 7.5), 0.5% 
Triton X-100, 1 mM EDTA, 1 mM EGTA, and 10 mM sodium fluoride, and 1 M NaCl 
or 150 mM NaCl, respectively]. The columns were washed a final time with 1 mL 
0.1% SDS before elution in 1 mL of 0.5% SDS (100°C, 5 min). Eluted kinases were 
reduced (dithiothreitol) and alkylated (iodoacetamide) prior to being concentrated 
with Amicon Ultra centrifugal filters (Millipore) and detergent was removed from the 
concentrated eluate by chloroform/methanol extraction. Protein pellets were 
resuspended in 50 mM HEPES (pH 8.0) and were digested overnight with 
sequencing grade modified trypsin (Promega). Peptides were dried down in a 
speed-vac and cleaned with C-18 spin columns (Pierce) according to the 
manufacturer instructions.  
Peptides were resuspended in 5% acetonitrile and 0.1% formic acid, and 25-
50% injected onto a Thermo Easy-Spray 75uM x 25cm C-18 column via an Easy 
nanoLC-1000. Peptides were separated as a single fraction on a 300 minute 
gradient (5-40% acetonitrile) and identified by a Q-Exactive mass spectrometer. 
Parameters: 3e6 AGC MS1, 80ms MS1 max inject time, 1e5 AGC MS2, 100ms MS2 
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max inject time, 20 loop count, 1.8 m/z isolation window, 45s dynamic exclusion. 
Spectra were identified using MaxQuant software and the Uniprot/Swiss-Prot 
database. Peptide abundance was calculated using label-free quantification (LFQ). 
Western Blotting and Antibodies 
Either MIB lysates were used directly for Western  blots, or cells were washed 
in cold PBS and harvested in NP-40 lysis buffer [0.1% NP-40, 150 mM NaCl, 50 mM 
Tris HCl (pH 8.0), 30 mM β-glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 Roche 
protease inhibitor tablet per 50 mL] for 10-30 minutes on ice. Lysates were frozen 
and thawed and clarified by centrifugation at 16,000 x g for 10 minutes. Protein 
content was determined by Bradford assay (Bio-Rad) using a CLARIOstar Optima 
plate reader (BMG Labtech). Equal amounts of protein were resolved on 10% SDS-
PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked 
with 5% non-fat dry milk in 1x TBS/0.1% Tween followed by overnight incubation 
with primary antibody at 4oC. HRP-conjugated secondary antibodies were incubated 
for 1 hour at room temperature. Blots were developed with PicoWest (Thermo) or 
ECL Prime (GE Healthcare) chemiluminescent reagent. Phospho-Src Y416, 
phospho-p70 S6K T421/S424, phospho-IKKα/β S176/S180, phospho-p90 RSK 
S380/ T359/ S363/ T573, Total p70 S6K, and Tubulin were purchased from Cell 
Signaling. vIL-6 and LANA antibodies were from Advanced Biotechnologies. HRP-
conjugated secondary antibodies were from Cell Signaling.  
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RESULTS 
The activated kinome in latent and lytic TREx BCBL1 PEL were compared by 
averaging values obtained from two independent experiments, and dividing the 
latent average over the lytic average and the lytic average over the latent average. 
Values were ranked, and the top 20 differentially activated kinases were reported for 
both latent and lytic cells (Table 4.1).  
 
Table 4.1: Top twenty differentially activated kinases in latent and lytic PEL. (A) Kinases 
activated in latent TREx-BCBL1 PEL. (B) Kinases activated in lytic TREx-BCBL1 PEL. 
 
We also picked up the KSHV encoded kinases, ORF21 and ORF36 (vPK), in 
the MIB/MS profiling. As expected, spectral hits for these kinases were only 
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identified in the lytic cells since they are both expressed exclusively during lytic 
reactivation (Figure 4.1).  
 
 
Figure 4.1: Viral kinases are isolated by MIB/MS. Quantification of peptides isolated and 
identified with MIB/MS that correspond to the viral kinases, ORF21 and ORF36, in latent 
and lytic TREx-BCBL1 samples. Samples were normalized to latent PEL.  
 
We also wanted to confirm changes in kinase activity by Western blot. Left 
over MIB lysates were analyzed by SDS-PAGE and Western blotting for the 
activation status of Src, p70 S6K, IKKα/β, and p90 RSK (Figure 4.2). 
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Figure 4.2: Analysis of specific kinase activation in latent and lytic TREx-BCBL1 PEL. 
MIB lysates were subjected to SDS-PAGE and Western blotting for phospho-Src Y416 (A), 
phospho- p70 S6K T421/S424 (B), phospho-IKKα/β S176/S180 (C), and phospho-p90 RSK 
S380/T359/S363/T573 (D). Tubulin was used as a loading control, and vIL-6 was used as a 
measure of lytic reactivation. Fold change values indicate the level of predicted kinase 
activation in lytic cells as compared to latent cells by MIB/MS. 
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DISCUSSION 
MIB/MS is a powerful tool to profile the active kinome in cells or tissues. 
There are a number of other ways of assessing global kinase activation, each with 
their own caveats. RNA sequencing can be used to determine which kinase genes 
are actually being transcribed in cells, however this does not indicate which kinases 
are expressed at the protein level, or if the kinase proteins are actually activated. 
Identifying kinases with proteomic mass spectrometry is challenging because they 
make up a relatively small portion of the expressed proteome (369). Furthermore, 
the presence of a kinase does not indicate its activation status.  Adenosine 
triphosphate (ATP) affinity probes have been utilized for profiling the kinome 
expression of cells since kinases bind ATP. The limitations of this method are that it 
is not selective for activated kinases, and kinases have inherently different ATP-
binding affinities which may skew quantified data (370). Titanium dioxide can be 
used to enrich for phospho-proteins prior to mass spectrometry (371); however this 
method can also enrich for non-kinase proteins that can be phosphorylated, such as 
STAT3. Furthermore, many kinases have inactivating phosphorylation sites, such as 
Tyr527 of Src kinase (372), so it is possible that inactive kinases are also enriched 
by titanium dioxide prior to mass spectrometry. Antibody arrays are available to 
quantify levels of active kinases with phospho-specific antibodies, but these are 
largely limited by the quality and availability of these antibodies as well as the low-
throughput nature of these arrays.  
The multiplex inhibitor bead method used for this work is unique and 
overcomes some of the caveats of other kinome profiling methods. The beads used 
110 
are coupled to several moderately selective kinase inhibitors and several pan-kinase 
inhibitors, which collectively can bind to the active site of the majority of expressed 
human kinases (350). The advantage of these beads is that they selectively bind 
only activated kinases, since kinase inhibitors are inherently designed to bind to the 
active site of active kinases. Samples are run over a stacked column of these beads, 
and bound active kinases are then eluted and subjected to mass spectrometry.   
We began by profiling the active kinome of TREx-BCBL1 PEL that harbor either a 
latent or lytic KSHV infection to determine how kinases are differentially activated in 
these two lifecycles. Understanding how various kinases are activated in different 
stages of the viral lifecycle may uncover reasonable kinase targets to drive infection 
towards the lytic lifecycle which is treatable with acyclovir and related compounds 
(366). Our kinome profiling recovered hundreds of active kinases present in latent 
and lytic infection, including the two kinases encoded by KSHV, ORF21 and ORF36 
(vPK) (Figure 4.1). We reported the top kinases that are differentially activated in 
latent and lytic cells (Table 4.1).  
 CAMK1D is a member of the calcium/calmodulin-stimulated protein kinase 
family, and plays a role in cell cycle progression. CAMK1 has specifically been 
implicated in regulating the transition into G1 phase, and is thought to activate cdk4 
and cyclin D1 to promote entry into G2/S (373, 374). Our MIB/MS data indicate that 
CAMK1D is activated in lytic cells (Table 4.1). KSHV does not rely on host DNA 
replication machinery to copy its genome since it expresses a viral DNA polymerase; 
however, promoting entry into the cell cycle may still be advantageous for the virus 
since the production of nucleotides, amino acids, and lipids - all important 
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components of infectious progeny virions - are ramped up by the host cell during 
entry into the cell cycle. It would be interesting to investigate if CAMK1D is activated 
by a specific KSHV lytic protein to initiate the cell cycle. On a related note, the 
MIB/MS data also identified several host cyclin dependent kinases (CDKs) that were 
highly activated during lytic replication, including CDK3 and CDK17. CDK3 is a key 
cell cycle regulator, and its inhibition results in cell cycle arrest (375). Interestingly, 
inhibition of CDKs that are critical for promoting the cell cycle also inhibits replication 
of another herpesvirus, herpes simplex virus (HSV) (376). It would also be 
interesting to investigate the lytic KSHV proteins that can induce activation of CDKs 
to promote entry into the cell cycle and successful lytic viral replication.  
 In latent PEL, the MIB/MS analysis suggests that the tyrosine kinase c-MET is 
highly activated as compared to lytic PEL. The ligand for c-MET is hepatocyte 
growth factor (HGF), and a previous study indicated that both HGF and c-MET are 
expressed and functional in PEL (377). Activation of HGF/c-MET is implicated in the 
development of many cancers and the inhibition of MET activity is an active area of 
focus for the development of cancer therapeutics (378). Interestingly, another group 
recently reported preliminary studies indicating that the HGF/c-MET pathway is 
highly active in PEL, and that use of a novel selective HGF/c-MET inhibitor induces 
PEL apoptosis via cell-cycle arrest and DNA damage in vitro and reduces PEL tumor 
expansion in vivo (Dai, Qin, et al. Unpublished results, Abstract presented at the 18th 
International Workshop on KSHV and Related Agents, Miami FL, July 2015). This 
work not only confirms our MIB/MS findings, but also emphasizes the potential 
impact of inhibiting kinases that are found to be highly active in our MIB/MS analysis.  
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 The MIB/MS data, as well as confirmatory Western blots, also found higher 
activation of p70 S6 kinase (S6K) in lytic PEL. Additionally, Western blots indicated 
higher p90 ribosomal S6 kinase (RSK) activation in lytic PEL as compared to latent 
PEL. The S6 kinases regulate and promote protein translation, an essential process 
for viral replication, so higher levels of these kinases would be expected during lytic 
replication.  A recent publication investigating phosphorylated kinases in latent and 
lytic KSHV-infected epithelial cells also noted higher S6K and RSK activation in lytic 
cells (379). They found that ORF45 plays a role in the activation of both of these S6 
kinases, and that activation of RSK is crucial for the production of infectious progeny 
(379, 380). Since S6K is downstream of a number of signaling pathways activated 
by various KSHV-encoded proteins, there are likely many viral mechanisms in 
addition to ORF45 that contribute to the activation of both S6K and RSK.   
 MIB/MS and subsequent Western blotting indicated higher activation levels of 
the tyrosine kinase Src and the NFκB regulators IKKα/β in lytic PEL. Src family 
kinases are a group of non-receptor tyrosine kinases that regulate cell growth and 
promote cellular transformation. They interact with a variety of receptor tyrosine 
kinases (RTKs) to induce diverse downstream signaling pathways. Src and the Src 
family member Lyn have been shown to be activated by several KSHV lytic proteins, 
including K1 and vGPCR, as well as by binding between the KSHV virion and 
EphrinA2, a known KSHV receptor (173, 381, 382). The NFκB pathway is implicated 
in inflammation, cell survival, and tumorigenesis, and activation of the IKKs is 
required for initiation of both canonical and non-canonical NFκB signaling. There are 
several KSHV lytic proteins known to activate NFκB, including K1, vGPCR and K15 
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(173, 218, 383). Since expression of these KSHV-encoded signaling proteins is 
induced during lytic reactivation, this provides a possible mechanism by which Src 
and IKK activation occurs during lytic reactivation.  
Some of the kinases we analyzed for phosphorylation status by Western blot 
did not match the activation status suggested by the MIB/MS results, such as p90 
RSK. There are several possibilities for this disparity: the first is that kinases often 
have multiple phosphorylation sites, some of which are activating and some of which 
are inhibitory. By probing for a single phosphorylation site on a particular kinase with 
a single antibody, we are not seeing the entire picture of that kinase’s activity. 
Another explanation for inconsistent data is that MIB/MS cannot normalize for 
differences in total levels of a kinase. For example, in Figure 4.2 D the total levels of 
p90 RSK vary substantially amongst samples. MIB/MS analyzes the total amount of 
activated kinase regardless of whether the activated form makes up 3% of that 
particular kinase or 99% of that particular kinase, which is a bias that must be taken 
into consideration when evaluating MIB/MS data.  
In conclusion, we profiled the activated kinome of latent and lytic BCBL1 PEL 
and identified many kinases that are differentially activated in latent and lytic 
infection. These data are interesting and intriguing, and leave much to be explored. 
Understanding how KSHV modulates the kinome of infected cells will have huge 
implications not only for viral infection, but also for potential therapeutics for KSHV-
associated malignancies.  
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CHAPTER 5: SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
  
GENERAL SUMMARY 
 My dissertation research, performed under the guidance of Dr. Blossom 
Damania, is focused on the broad goal of further understanding how KSHV interacts 
with and modulates the host cell environment to promote pathogenesis. My project 
took advantage of several different approaches to investigate this question. I first 
performed detailed characterization of how a single KSHV protein, vIL-6, interacts 
with and modulates the cellular environment. This project utilized both proteomics 
and transcriptomics to unravel the intricacies of vIL-6 function inside the cell. My 
project then investigated the impact of latent and lytic KSHV infection on the host 
cell kinome. Cellular kinases regulate nearly every cellular function, and 
dysregulated kinase signaling is implicated in the development of many cancers. 
Understanding further how KSHV and all of its encoded components interact with 
and modulate the host cell environment and host kinases will be essential to 
developing efficacious strategies to combat infection and associated malignancies.  
 In chapter one, the general biology and manifestations of KSHV infection are 
discussed. Chapter two investigates the interaction of the KSHV protein vIL-6 with 
cellular proteins, and focuses on an interaction of vIL-6 with the protein HYOU1. 
HYOU1 was found to be important for maintaining vIL-6 protein levels in the cell and 
facilitating vIL-6-mediated STAT3 signaling, cell migration, and nutrient-deprived 
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survival in endothelial cells. Chapter three delves into the impact of intracellular vIL-6 
expression on the endothelial cell transcriptome. My work uncovered that vIL-6 
upregulates expression of the host adhesion and angiogenesis factor CEACAM1, 
and that CEACAM1 facilitates vIL-6-mediated migration of endothelial cells. 
Additionally, I found that KSHV infection also upregulates CEACAM1, further 
implicating this host protein in viral pathogenesis. In chapter four, I utilized a novel 
kinome profiling technique to probe the activated kinome in latent versus lytic KSHV 
infection in PEL. This work could shape the development of targeted therapeutics to 
counteract dysregulated kinase activation in KSHV-associated cancers.   
 These diverse projects have come together to achieve my objective of further 
characterizing how KSHV interacts with and manipulates the host cell. Part of my 
graduate work investigates how one specific viral protein manipulates the host cell, 
and the other part broadly probes how the entire virus alters global signaling 
pathways within infected cells. This final chapter meshes these distinct approaches 
into the overall objective of my graduate research, and highlights future directions 
that will extend this work to bring a fuller understanding of KSHV biology and 
pathogenesis.  
 
KSHV-ASSOCIATED MALIGNANCIES AND MECHANISMS OF PATHOGENESIS 
 Since its discovery in 1994, KSHV has been linked to three human 
malignancies, KS, PEL, and MCD. KS is an endothelial cell tumor that presents as 
highly vascularized skin lesions, PEL is a clonal expansion of latently infected 
plasma cells in the pleural cavities, and MCD is an expansion of plasmablasts within 
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B cell follicles. KSHV is also associated with two rare immune activation syndromes 
called KSHV-associated inflammatory cytokine syndrome and KSHV immune 
reconstitution inflammatory syndrome, which present with high KSHV viral loads and 
immune system flare ups.  
 KSHV infection exists in a latent or lytic lifecycle, and it is thought that its 
ability to transition between these stages is one mechanism by which the virus 
evades host immune detection. During latency, KSHV expresses a limited set of viral 
proteins and viral miRNAs, many of which have oncogenic and transforming 
properties. KSHV primarily defaults to a latent infection in the host, so understanding 
the mechanisms by which latency proteins, such as LANA, drive pathogenesis in the 
host cell has been the focus of many scientific studies. LANA tethers the viral 
episome to the host chromosome and influences the oncogenic capability of latently 
infected cells by modulating the tumor suppressor p53, GSK3β, myc, and 
telomerase (91, 94, 95, 97). The viral miRNAs are also highly expressed in latency, 
and have diverse functions ranging from latency maintenance to immune evasion 
and cell proliferation.  
 During lytic reactivation, the viral replication and transcription activator (RTA) 
protein initiates a complex transcriptional cascade that results in expression of all 
viral non-structural and structural proteins. Many lytic proteins have been 
characterized as pro-growth signaling proteins, including K1, vIL-6, vGPCR, and 
K15, amongst others (199, 384). KSHV lytic proteins have been shown to activate 
major host proliferation and pro-inflammatory pathways, including the MAPK, 
PI3K/Akt/mTOR, JAK/STAT, PKC, and NF-κB pathways. Identifying cellular 
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pathways that are stimulated by lytic KSHV proteins and unraveling the underlying 
mechanisms by which they activate these pathways will not only enrich our 
knowledge of KSHV biology, but may also guide the development of targeted 
therapeutics to reduce pathogenic signaling.  
 In addition to utilizing latency to hide from the host immune system, KSHV 
has an arsenal of factors that also prevent its detection by and activation of antiviral 
immune defenses. Although KSHV has several mechanisms of evading the adaptive 
immune response, numerous studies have focused on the interplay between KSHV 
and the innate immune system. KSHV can be detected by various innate immune 
sensors, including the TLRs, RLRs, NLRs, and cGAS/STING (281, 385), but it also 
encodes viral proteins including the viral IRFs, ORF63, and ORF45, that potently 
blunt these responses to reduce expression and release of interferon β and IL-1β 
(225, 278). KSHV also expresses proteins that inhibit complement activation and 
detection by NK cells (242, 288). Further investigation of how KSHV evades immune 
detection may lead to alternative therapeutic strategies that boost the innate immune 
system to allow the host to successfully defend against the virus and eliminate 
infection. 
 
MODULATION OF KSHV VIRAL INTERLEUKIN 6 FUNCTION BY HYPOXIA 
UPREGULATED PROTEIN 1 
 KSHV encodes a homolog of the human interleukin 6 cytokine (hIL-6), called 
viral interleukin 6 (vIL-6). These proteins have significant structural and functional 
similarity, so many early studies on vIL-6 investigated how it influenced cells after 
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being exogenously applied in culture media. Elegant studies by Meads et al in 2004 
identified some striking differences between hIL-6 and vIL-6 secretion 
characteristics: vIL-6 was found to be secreted over 8 fold slower than hIL-6, and 
vIL-6 had a glycosylation profile distinct from typical secreted cytokines (206). A 
subsequent study discovered the ability of vIL-6 to form tetramers with the gp130 
subunit of the IL-6 receptor within the endoplasmic reticulum (ER) compartment to 
induce functional intracellular signaling in the absence of the IL-6R gp80 subunit 
(207). Collectively, these studies strengthened the evidence that vIL-6 largely 
functions inside the cell. We therefore hypothesized that vIL-6 must interact with 
host proteins that help promote the function of vIL-6, so the objective of this project 
was to identify and characterize novel cellular interaction partners of vIL-6.  
 The results of this work were published in the Journal of Virology (313). I 
initiated this project by performing a vIL-6 immunoprecipitation followed by mass 
spectrometry to identify bound proteins. Protein mass spectrometry is extremely 
sensitive, and data sets are notorious for containing many false positive hits. 
Proteins that had higher spectral counts in the vIL-6 samples as compared to an 
empty vector control sample were categorized as potential hits, and we became 
interested in one particular protein that had a comparable number of spectra 
identified in the vIL-6 samples to gp130. This protein was called hypoxia upregulated 
protein 1 (HYOU1), which is an ER chaperone protein that promotes angiogenesis 
and prevents hypoxia-induced cell death.  
 After confirming that vIL-6 and HYOU1 interact by coimmunoprecipitation 
experiments, I determined that HYOU1 is expressed in tissue from KSHV 
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malignancies. I then found that HYOU1 plays a role in maintaining the level of 
secreted and intracellular vIL-6 protein. To determine if HYOU1 modulates vIL-6 
function, I examined the impact of HYOU1 on vIL-6-induced signaling, and found 
that in the absence of HYOU1, vIL-6 was less able to interact with gp130 and 
activate STAT3. I then performed biological assays in endothelial cells and found 
that HYOU1 was critical for vIL-6-mediated migration and serum-starved survival. 
Finally, I showed that HYOU1 also facilitates hIL-6-induced STAT3 signaling, and 
that HYOU1 can bind hIL-6 when the human cytokine is in a modified form that 
restricts its localization to the ER compartment. I speculate that HYOU1 interacts 
transiently with wild type hIL-6 as it transitions out of the ER to be secreted, but 
because hIL-6 remains in the cell so briefly I was unable to detect it in a co-
immunoprecipitation experiment. 
 While investigating the mechanism by which HYOU1 affects vIL-6 mediated 
migration, I performed a chemokine array and identified CCL2 as a chemokine that 
is upregulated by vIL-6 in a HYOU1-dependent manner. Since vIL-6 has been 
implicated in migration and angiogenesis, it is likely that there are other important 
chemokines and cytokines whose expression is modified by vIL-6. An interesting 
future direction is to perform a more thorough profiling of secreted factors from vIL-6-
expressing cells, which may give further insight into the mechanisms by which vIL-6 
promotes increased movement, survival, and angiogenesis in endothelial cells. 
Another future direction could be to explore the vIL-6 residues or domains at the 
interface of the HYOU1-vIL-6 interaction. I attempted to mutate sizeable domains of 
vIL-6 but was unable to ablate the interaction, which suggests that there may be 
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multiple points of contact between vIL-6 and HYOU1. This would not be surprising, 
since HYOU1 is a large chaperone protein, but understanding where it interacts with 
vIL-6 may give insight into HYOU1’s possible interaction with and effect on hIL-6. 
Finally, there have been no other reports investigating HYOU1 in KSHV biology, so it 
is unknown whether KSHV infection is impacted by HYOU1 expression or if HYOU1 
plays a role in the processing or function of other viral proteins. These would be 
exciting avenues for future research. 
 
KSHV VIRAL INTERLEUKIN 6 MODULATES ENDOTHELIAL CELL MOVEMENT 
BY UPREGULATING CELLULAR GENES INVOLVED IN MIGRATION 
 This work was a continuation of my first project that investigated protein 
binding partners of vIL-6 that promoted vIL-6 function. While some vIL-6 functions 
have been elucidated by our lab and others, an area that has not been thoroughly 
explored is how this viral cytokine impacts the transcriptional profile of endothelial 
cells to modulate the host cell environment or host cell function.  The objective of 
this work was to identify major pathways altered by vIL-6 expression, and identify if 
there are host genes that vIL-6 induces to manipulate cellular function. 
 A previous study examined expression of a limited set of host genes with the 
exogenous application of bacterially-derived vIL-6 (62). More recently, it has been 
discovered that vIL-6 requires mammalian glycosylation machinery for optimal 
function, and that an appreciable amount of vIL-6 signaling occurs intracellularly 
(207, 341). My work therefore revisited the impact of vIL-6 on host gene expression, 
but took an approach using intracellular vIL-6 expression and endothelial cells, 
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which are a relevant cell type for KSHV biology. Microarray results and subsequent 
analysis with Ingenuity Pathway Analysis identified numerous biological function 
pathways that were significantly altered by vIL-6 expression, including cellular 
movement.  
 A host gene called CEACAM1 was identified in several of the cellular 
movement sub-pathways, and this protein is known to promote endothelial cell 
migration and angiogenesis. I confirmed that this gene is upregulated at both the 
message and protein level in endothelial cells that express vIL-6, as well as in 
endothelial cells with latent or de novo KSHV infection. Chemical inhibition of STAT3 
reduced vIL-6-mediated upregulation of CEACAM1, suggesting that vIL-6 induces 
CEACAM1 expression via the JAK/STAT pathway. Interestingly, exogenously 
applied hIL-6 did not induce CEACAM1, which could be due to the inherently weaker 
activation of STAT3 signaling by hIL-6, or to a unique intracellular mechanism 
employed by vIL-6 that results in CEACAM1 upregulation. Finally, I show that 
CEACAM1 plays a role in promoting vIL-6-mediated migration of endothelial cells. 
 There are a number of interesting questions that remain for this project. 
Despite the similarities between vIL-6 and hIL-6, there are also striking differences 
between these cytokines with regard to localization, secretion, and glycosylation. It 
would be interesting to evaluate and compare the microarray profiles of cells with 
intracellular expression of hIL-6 or vIL-6 and exogenously applied hIL-6 or vIL-6. 
This may elucidate not only differences in how vIL-6 and hIL-6 modulate cellular 
gene expression, but also whether these changes are impacted by where signaling 
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initiates (extracellular or intracellular). This work could also provide insight into why 
exogenously applied hIL-6 does not induce CEACAM1 expression. 
 A number of other interesting genes associated with cellular movement were 
modulated by vIL-6. Pleiotrophin (PTN) was upregulated about 25 fold by vIL-6 in 
the microarray, and about 8.5 fold with follow-up qPCR (data not shown). PTN is a 
secreted factor in the midkine chemokine family that promotes endothelial cell 
migration and angiogenesis by inducing expression and secretion of VEGF and 
CCL2 (386, 387). Tumor necrosis factor superfamily member 15 (TNFSF15; also 
called TL1A) is a protein secreted by endothelial cells to negatively regulate 
neovascularization, and its expression has been shown to be decreased by IFNγ in 
endothelial cells and decreased by VEGF and CCL2 in macrophages and T 
regulatory cells (388, 389). The microarray data as well as subsequent qPCR 
analysis of TNFSF15 indicated that this host transcript was approximately 10 fold 
reduced in vIL-6-expressing endothelial cells (data not shown). vIL-6 is known to 
increase VEGF and CCL2, so it is possible that modulation of PTN by vIL-6 causes 
induction of VEGF and CCL2 which then downregulates TNFSF15 to collectively 
contribute to the increased migration and angiogenesis observed with vIL-6 
expression. A more thorough investigation of these pathways may further elucidate 
the mechanism by which vIL-6 modulates these host genes.  
 While performing de novo KSHV infections in endothelial cells, I observed 
that knockdown of CEACAM1 increased viral gene expression at 30 hours post 
infection of primary HUVEC (data not shown). An in vivo study of MHV-68 in 
CEACAM1-knockout mice found less robust lytic infection but increased viral load 
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and splenomegaly during latent infection in CEACAM1-null mice (345). This 
phenotype was later found to be mediated by natural killer cells (346). An interesting 
future direction would be to probe the reason for increased viral gene expression 
following de novo infection in CEACAM1-knockdown primary HUVEC. It is possible 
that CEACAM1 impedes viral entry, or that signaling from the cytoplasmic 
CEACAM1 ITIM domain blocks signaling through pathways such as FAK, PI3K, Src, 
and MAPK to abrogate delivery of capsids to the nucleus. Alternatively, it is possible 
that CEACAM1 somehow promotes latency, and KSHV upregulates CEACAM1 to 
drive infected cells away from lytic replication and into latency, to evade immune 
detection. Pursuing these questions may elucidate why CEACAM1-knockdown 
endothelial cells have increased viral gene expression following de novo infection, 
which could uncover interesting and important implications for CEACAM1 in KSHV 
biology.  
 Collectively, the work discussed in chapters 2 and 3 identify novel ways in 
which vIL-6 interacts with and modulates the host cell environment. I identified a 
host protein, HYOU1, which contributes to vIL-6 function by supporting vIL-6 
signaling through the gp130 subunit of the IL-6 receptor. I also found that 
intracellular vIL-6 modulates the expression of many host genes associated with cell 
movement, including the host adhesion factor CEACAM1, which contributes to vIL-6-
mediated endothelial cell migration. My working model suggests that intracellular 
ER-localized vIL-6 is stabilized by the chaperone HYOU1, which promotes vIL-6 
signaling through the IL-6 receptor. This increases STAT3 activation, which drives 
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expression of a number of host genes that promote vIL-6-mediated biological 
functions, such as migration, angiogenesis, and survival (Figure 5.1). 
 
 
Figure 5.1: A model for the mechanism of action of intracellular vIL-6. 
  
 Since KSHV expresses over eighty open reading frames in addition to viral 
miRNAs and long non-coding RNAs, determining the significance and contribution of 
each viral component with regard to disease pathogenesis is often complex. In the 
context of cancer pathogenesis, I speculate that the main role of vIL-6 is to induce a 
pro-inflammatory environment that results in the increased secretion of chemokines, 
cytokines, and growth factors. Collectively these factors may promote the growth 
and migration of infected cells, thus encouraging transformation and tumorigenesis. 
The presence of a pro-inflammatory environment may also provide the necessary 
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cellular stresses to induce viral reactivation in some cells to allow for the propagation 
of the virus. Additionally, vIL-6-induced chemokines may result in the recruitment of 
other susceptible immune cells, thus providing new host cells to help perpetuate 
KSHV infection. It is also important to consider the role of vIL-6 during asymptomatic 
KSHV infection, since only a fraction of patients with KSHV develop KSHV-
associated malignancies. I speculate that vIL-6 levels are likely much lower (if 
expressed at all) during asymptomatic KSHV infection since the level of vIL-6 
positively correlates with prognosis in MCD (59, 60). It has not been investigated if 
vIL-6 is present in asymptomatic KSHV infection, but if expressed, I hypothesize that 
small amounts of vIL-6 would still promote a mildly inflammatory environment: 
enough to promote a low level of viral persistence without inducing pathogenesis. 
KSHV and closely related herpesviruses are the only human viruses known to 
express a homolog of human IL-6, and while my work has advanced the field’s 
understanding of vIL-6, the comprehensive role of this unique, multifaceted viral 
protein in disease and KSHV biology remains to be elucidated.     
 
ALTERATION OF THE HOST CELL KINOME BY LYTIC AND LATENT KAPOSI’S 
SARCOMA ASSOCIATED HERPESVIRUS INFECTION 
 This research was performed in collaboration with Dr. Gary Johnson’s lab at 
the University of North Carolina at Chapel Hill. His lab developed a novel method to 
specifically profile the activated kinome of cell or tissue samples, and the goal of our 
collaboration was to identify differentially activated kinases in lytic and latent PEL.  
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The MIB/MS analysis picked up several hundred kinases among our samples, and I 
ranked the top differentially activated kinases in the latent and lytic PEL (Table 4.1). 
The MIBs also isolated the two KSHV-encoded kinases, ORF21 and ORF36, which 
suggests that they are activated in lytic cells and can be bound by known kinase 
inhibitors. There are a number of future directions for this project, the first of which is 
confirming activation of top kinases identified in the MIB/MS comparison of latent 
and lytic PEL. Ideally, radioactive kinase assays should be used to probe the 
activation of selected kinases since Western blots analyzing phosphorylation at 
particular kinase residues have caveats, as described in chapter 4.  
Due to the rarity of PEL and the lack of an established treatment protocol, 
clinicians will sometimes treat PEL patients with a variety of novel drugs that target 
signaling pathways, with some efficacy. These include chemical inhibitors of NFκB, 
PI3K/AKT/mTOR, and JAK/STAT, VEGF, and CD30. Using kinase inhibitors to 
reactivate KSHV from latency will induce lysis of infected cells or sensitize cells to 
treatment with acyclovir-like compounds. Analyzing the kinome of latent versus lytic 
PEL may identify key kinases that can be targeted to accomplish lytic reactivation. 
For example, inhibition of TLK2 by siRNA knockdown induces lytic reactivation 
(368). Therefore, another future direction of this project is to determine if inhibition or 
activation of specific kinases in latent PEL can drive cells towards lytic reactivation 
that is treatable with acyclovir or related compounds.  
Collectively, this project has provided preliminary evidence that there are 
differentially activated kinases in latent and lytic PEL. This project has numerous  
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future directions that will be necessary to confirm and characterize the activation of 
these cellular kinases, since this will provide critical direction for the development 
and use of specific kinase inhibitors to treat patients with PEL.   
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